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Neuropharmacological Mechanisms Underlying Incentive Salience and Stress
Abstract
Anhedonia, the lost of interest or pleasure in normally enjoyable activities, is a core clinical feature of
major depressive disorder (MDD). Although the term encompasses both consummatory and appetitive
components, empirical findings suggest that anhedonia is more closely associated with deficits in
motivational processing as opposed to alterations in hedonic valuation of rewards. A growing body of
evidence points to a role for the mesolimbic dopamine (DA) system in the etiology of motivational
deficits. However, the neurobiological mechanisms underlying the manifestation of anhedonic behavior
are still not well understood. Given the frequent presentation of anhedonia in stress-related psychiatric
disorders, we hypothesized that exposure to stressors disrupts brain signaling pathways that would
typically facilitate reward processing. The experiments in this thesis utilized the novelty-induced
hypophagia (NIH) test, a motivational conflict paradigm, to examine the effects of stress on neural
processes associated with the attribution of incentive salience to salient stimuli. Using in vivo
microdialysis, we assessed the role of nucleus accumbens (NAc) DA transmission in mediating
conditioned approach behavior for food reward, and established that stress exposure blunts NAc DA
response to palatable food and reduces incentive salience for the reward, as defined by increased latency
to approach. Pretreatment with the mixed action opioid drug buprenorphine prevented the behavioral and
neurochemical effects of stress in this paradigm, implying a role for the brain opioid system in mitigating
the negative effects of stress on incentive behavior. Using a combination of genetic and pharmacological
tools, the role of individual opioid receptors in restoring approach behavior suppressed by stress in the
NIH test was next dissected. These studies identified the mu opioid receptor as a critical mediator of
approach behavior and a potential pharmacological target for alleviating prodepressive behaviors during
stress. Lastly, the interaction between elevated stress hormones and treatment with the selective
serotonin reuptake inhibitor fluoxetine, a commonly used antidepressant, was investigated on incentive
behavior in the NIH paradigm. We found that exogenous corticosterone exposure facilitated reduced
approach behavior caused by exposure to chronic fluoxetine in C57BL/6 mice. Thus, exposure to stress
hormones enabled fluoxetine to produce a behavior modeling a therapeutic response in a strain of mice
that are otherwise insensitive to this antidepressant drug. Collectively, these findings further expand our
understanding of the mechanisms underlying stress-induced affective behavior and antidepressant drug
treatments.
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ABSTRACT

NEUROPHARMACOLOGICAL MECHANISMS UNDERLYING
INCENTIVE SALIENCE AND STRESS

Shivon A. Robinson
Irwin Lucki

Anhedonia, the lost of interest or pleasure in normally enjoyable activities, is a core
clinical feature of major depressive disorder (MDD). Although the term encompasses
both consummatory and appetitive components, empirical findings suggest that
anhedonia is more closely associated with deficits in motivational processing as
opposed to alterations in hedonic valuation of rewards. A growing body of evidence
points to a role for the mesolimbic dopamine (DA) system in the etiology of motivational
deficits. However, the neurobiological mechanisms underlying the manifestation of
anhedonic behavior are still not well understood. Given the frequent presentation of
anhedonia in stress-related psychiatric disorders, we hypothesized that exposure to
stressors disrupts brain signaling pathways that would typically facilitate reward
processing. The experiments in this thesis utilized the novelty-induced hypophagia
(NIH) test, a motivational conflict paradigm, to examine the effects of stress on neural
processes associated with the attribution of incentive salience to salient stimuli. Using in
vivo microdialysis, we assessed the role of nucleus accumbens (NAc) DA transmission
in mediating conditioned approach behavior for food reward, and established that stress
exposure blunts NAc DA response to palatable food and reduces incentive salience for
the reward, as defined by increased latency to approach. Pretreatment with the mixed
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action opioid drug buprenorphine prevented the behavioral and neurochemical effects of
stress in this paradigm, implying a role for the brain opioid system in mitigating the
negative effects of stress on incentive behavior. Using a combination of genetic and
pharmacological tools, the role of individual opioid receptors in restoring approach
behavior suppressed by stress in the NIH test was next dissected. These studies
identified the mu opioid receptor as a critical mediator of approach behavior and a
potential pharmacological target for alleviating prodepressive behaviors during stress.
Lastly, the interaction between elevated stress hormones and treatment with the
selective serotonin reuptake inhibitor fluoxetine, a commonly used antidepressant, was
investigated on incentive behavior in the NIH paradigm. We found that exogenous
corticosterone exposure facilitated reduced approach behavior caused by exposure to
chronic fluoxetine in C57BL/6 mice. Thus, exposure to stress hormones enabled
fluoxetine to produce a behavior modeling a therapeutic response in a strain of mice that
are otherwise insensitive to this antidepressant drug. Collectively, these findings further
expand our understanding of the mechanisms underlying stress-induced affective
behavior and antidepressant drug treatments.
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Overview of depression
Major Depressive Disorder (MDD) is one of the most common forms of psychiatric
illness existing today, with a lifetime prevalence of 17% in the US and 4% worldwide
(Kessler et al., 2003). MDD is characterized by the presence of at least one of two major
symptoms, depressed mood or the lost of interest or pleasure in daily activities, in
addition to at least five secondary symptoms for a period of two or more weeks (DSM-VTR, American Psychiatric Association). Secondary symptoms of MDD span a wide
range of somatic, cognitive, and emotional deficits, including psychomotor agitation or
retardation, diminished ability to concentrate, and feelings of worthlessness or excessive
guilt. This combination of symptomology is incredibly disruptive to daily functioning and
is consistently associated with impaired productivity and reduced job retention (Beck et
al., 2011). The economic impact of lost productivity due to depression is estimated to
amount to over $30 billion per year in the United States alone (Stewart et al., 2003). The
chronicity of depression further adds to the debilitating nature of this condition. As many
as 50% of people who recover from a depressive episode will experience an additional
episode, typically within five years of the initial episode (Belsher and Costello, 1988;
Kupfer and Frank, 2001; Burcusa and Iacono, 2007). Moreover, individuals diagnosed
with MDD are at increased risk to develop other serious medical illnesses, such as heart
disease (Lett et al., 2004) and stroke (Williams et al., 2004). In terms of years lost to illhealth or early death, MDD is considered one of the most disabling medical conditions
and is predicted to be among the top three contributors to the worldwide burden of
disease by 2030 (Mathers and Loncar, 2006).
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Despite the availability of antidepressant medications, MDD continues to be a
challenging disorder to treat. Results from the Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study, the largest longitudinal randomized study of
antidepressant efficacy to date, showed that the frequently used selective serotonin
reuptake inhibitor (SSRI) citalopram produced a remission rate of around 30% (Trivedi et
al., 2006). Furthermore, many of the participants who achieved remission did so after 8
weeks of treatment or later. Approximately 30-60% of depressed individuals do not
respond to the first antidepressant prescribed and an estimated 15-30% fail to respond
to multiple treatments and are considered treatment-resistant (Cain, 2007; Berlim et al.,
2008). These alarming statistics highlight the importance of advancing our
understanding of the biological mechanisms underlying depression to develop more
efficacious and faster-acting therapies for the treatment of MDD. 	
  
Anhedonia as a depressive endophenotype
The investigation into the neurobiological mechanisms that govern the onset and
maintenance of depression has been hindered in part by the broad diagnostic
characterization of MDD. The currently used system of classification criteria for MDD
encompasses a wide range of symptoms that differ in severity, onset, and recurrence
(DSM-V-TR, American Psychiatric Association) and are likely mediated by different,
though possibly related, physiological processes (Charney and Manji, 2004). For
example, patients diagnosed with depression may either sleep more than normal or
suffer from insomnia and report their appetite for food is greater or less than normal. The
heterogeneous nature of MDD, as it is presently defined, severely limits the likelihood of
discovering an etiological course consistent between all depressed individuals. A more
appropriate strategy may be to focus research efforts on endophenotypes, narrowly
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defined behavioral dimensions and biological measures that span traditional diagnostic
criteria. The recently described research domain criterion (RDoC) framework
emphasizes deconstruction of psychiatric syndromes into fundamental neurobiological
components that can then be mapped onto genetic, molecular, cellular, and behavioral
processes (Cuthbert, 2014) This approach allows for identification of the “downstream”
mechanisms underlying specific clinical phenotypes and the “upstream” consequences
of physiological processes (Hasler et al., 2004). The endophenotype system operates on
the assumption that the biological processes regulating the manifestation of individual
endophenotypes are fewer and less multifaceted than those of the psychiatric entity as a
whole. Whether or not this is the case is yet to be determined. Nevertheless, closer
examination into endophenotypes of depression has the potential to yield important
findings and implications for the classification and subsequent treatment of depressive
disorders (Berghorst and Pizzagalli, 2010).
The evaluation of endophenotypes is based on several criteria including
heritability, specificity, and biological and clinical plausibility (Tsuang et al., 1993). Of the
many psychopathological endophenotypes associated with depression (cognitive
deficits, REM sleep abnormalities, and psychomotor changes to name a few), impaired
reward function has the most compelling empirical evidence and broadest applicability
(Hasler et al., 2004; Pizzagalli et al., 2005). Anhedonia, clinically defined as diminished
interest or pleasure in response to stimuli that were previously perceived as rewarding in
a premorbid state, is one of two required symptoms for the diagnosis of MDD (DSM-VTR, American Psychiatric Association). Approximately 37% of individuals with
depression experience clinically significant anhedonia (Pelizza and Ferrari, 2009)..
Blunted reward sensitivity and diminished motivational drive are strong predictors for the
diagnosis of MDD (Zimmerman et al., 2006; Treadway and Zald, 2013; Pizzagalli, 2014).
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Moreover, clinical studies indicate a familial association and heritability of anhedonic
endophenotypes in depression (Bogdan and Pizzagalli, 2009; Sieradzka et al., 2015).
Although hedonic deficits are commonly observed in other psychiatric disorders, such as
schizophrenia and post-traumatic stress disorder, anhedonia within these illnesses is
often associated with the presentation of depressive-like symptoms (Loas et al., 1999;
Kashdan et al., 2006; Volkow et al., 2011). In regards to the biological underpinnings of
anhedonia, multiple lines of evidence from both clinical and preclinical sources support a
role for the brain reward system.
Reward sensitivity and processing in anhedonia
The most well-characterized reward circuit of the brain is comprised of dopaminergic
neurons originating in the ventral tegmental area (VTA) that project to and innervate
several limbic and cortical structures regions, including the nucleus accumbens (NAc),
amygdala, hippocampus, and medial prefrontal cortex (mPFC). These structures are
interconnected through reciprocal glutamatergic connections that are further modulated
by GABAergic interneurons. Notably, dopaminergic projections from the VTA to the NAc
have been shown to mediate the reinforcing properties of both natural rewards and
drugs of abuse. Presentation of a rewarding stimulus produces phasic elevation of
dopamine (DA) levels in the NAc, whereas depletion of DA in this region reduces reward
responsiveness and reward-seeking behavior (Ikemoto and Panksepp, 1999). DA acts
primarily on two subfamilies of G-protein coupled receptors (GPCRs) known as D1-like
and D2-like receptors (Cooper et al., 2003). Stimulation of D1-like receptors increases
adenylate cyclase activity, while stimulation of D2-like receptors decreases adenylate
cyclase activity (Surmeier et al., 2007). Activation of DA receptors within the striatum
modulates the sensitivity of medium spiny neurons to excitatory glutamatergic input from
5	
  
	
  

corticolimbic structures (Hernandez-Lopez et al., 2000; Surmeier et al., 2007).
The proposed functional role of the midbrain DA system in reward processing
has deviated over time. Early studies suggested that DA directly produced the hedonic
impact, or “liking”, of a pleasant stimulus (Wise, 1985; Koob and Le Moal, 1997). This
concept was later challenged by taste reactivity studies which demonstrated that
depletion of DA in rodent forebrain and striatal regions does not alter hedonic impact to
rewards, suggesting that mesocorticolimbic DA activity is not necessary for “liking”
(Berridge et al., 1989; Berridge, 2000). Seminal work conducted by Schultz et al. (1997)
established a role for DA in the learning processes associated with reward response. In
these studies, monkeys presented with appetitive stimuli, but not aversive, exhibited
phasic activation of midbrain neurons. Repeated pairings of environmental cues with a
rewarding stimulus shifted the temporal onset of phasic activation from the time of
reward delivery to the time of cue presentation. Moreover, the basal firing of DA neurons
was distinctly suppressed in trials that the reward was not presented after presentation
of the conditioned cue. These observations gave rise to the reward prediction error
hypothesis, which posits that DA encodes the discrepancy between predicted and
experienced reward, thus regulating reinforcement-dependent learning (Schultz et al.,
1997; Hyman et al., 2006; Wise, 2008; Glimcher, 2011). Building upon these
electrophysiological observations, Berridge and Robinson (1998) proposed incentive
salience theory, which describes a role for DA in mediating the learned reward
associations that attribute motivational “wanting”, but not “liking”, to a previously neutral
stimulus (Berridge, 2012). Indeed, several studies have demonstrated dissociation
between motivational behavior and hedonic valuation in response to rewarding stimuli.
For example, highly rewarding drugs of abuse have repeatedly been shown to induce
conditioned taste aversion in rodents at doses that would be readily self-administered
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(Berger, 1972; Cappell and Le Blanc, 1973; Cappell et al., 1973; Wise et al., 1976; White
et al., 1977). Although, more recent studies have argued that avoidance of cues
associated with drugs of abuse is independent of taste aversion, and may instead reflect
conditioned fear (Parker, 2003). On the other hand, DA antagonists and NAc DA
depletion have been shown to distinctly suppress effort-related behavioral responding for
food reward without diminishing food consumption in low-effort conditions (Aberman and
Salamone, 1999; Salamone et al., 2002). Thus, mesolimbic DA activity within the NAc is
likely involved in the effort-based and goal-directed behavior that underlies motivational
“wanting” of an attractive stimulus.
Diagnostic assessments of anhedonia in depressed individuals have traditionally
emphasized the aspect of “loss of pleasure” (Treadway and Zald, 2013). Although, MDD
patients often report diminished general positive affect and reduced intensity of
emotional experiences (Germans and Kring, 2000; Naragon-Gainey et al., 2009),
several studies indicate that individuals presenting with anhedonia do not differ from
healthy controls in perceiving the pleasantness of an emotionally salient stimulus
(Berenbaum and Oltmans, 1992; Burbridge and Barch, 2007; Etain et al., 2007; Sherdell
et al., 2012). Instead, clinical evidence suggests that anhedonia in depression is
characterized primarily by deficits in affective processing that may underlie reduced
motivational drive for reward (Pizzagalli, 2014). Laboratory studies utilizing
reinforcement paradigms demonstrate that MDD patients fail to develop a response bias
towards more rewarding stimuli (Pizzagalli et al., 2005; Pizzagalli et al., 2008), an effect
that has been shown to be associated with striatal function in monkeys (Lauwereyns et
al., 2002). Neuroimaging studies have linked MDD to reduced grey matter volume within
striatal regions (Kim et al., 2008; Matsuo et al., 2008; Pizzagalli et al., 2008; Wacker et
al., 2009) and diminished activation of the ventral striatum to anticipation of rewards
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(Forbes, 2011; Smoski et al., 2011), reward prediction errors (Steele et al., 2007; Kumar
et al., 2008), and receipt of reward (McCabe et al., 2009; Pizzagalli et al., 2009; Smoski
et al., 2009; Wacker et al., 2009). Moreover, severity of anhedonic symptoms is
positively correlated with reduced ventral striatum response to rewarding stimuli
(Keedwell et al., 2005; Epstein et al., 2006). Altered striatal activity in MDD may be a
result of generally reduced DA activity. MDD patients exhibit lower levels of
cerebrospinal homovanilic acid, the primary metabolite of DA, signifying reduced basal
levels of DA in depression (Lambert et al., 2000; Mitani et al., 2006). Furthermore,
positron emission topography imaging studies report reduced DA transporter binding in
the striatum of depressed patients with anhedonic symptoms (Sarchiapone et al., 2006).
Altogether, these findings suggest a link between alterations in mesocorticolimbic DA
functioning and impaired reward processing in anhedonia.
Interaction of brain stress and reward systems in depression
A substantial body of evidence supports a pathophysiological role of stress in
depression. Approximately 80% of depressive episodes are reported to be preceded by
a stressful life event (Mazure, 1998; Hammen, 2005). However, prospective longitudinal
studies have also found exposure to chronic stressors (i.e. persisting for more than 12
months) rather than acute stressful episodes to have a significant influence on the onset
and course of depression (Caspi et al., 2003; Harkness and Monroe, 2006). Exposure to
chronic stress is associated with more frequent recurrences (Lethbridge and Allen,
2008), increased resistance to treatment (Amital et al., 2008), and more severe
depressive symptoms (Leskela et al., 2006). Interestingly, the association between
stress and depression weakens after multiple depressive episodes (Kendler et al.,
1998), suggesting that factors aside from stress reactivity are more closely associated
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with recurrent rather than initial depressive episodes.
Stress is also strongly associated with the manifestation of anhedonic behavior.
Acute stress has been shown to impair reward responsiveness within healthy
populations, particularly in individuals who exhibited greater cortisol reactivity to the
stressor (Berghorst et al., 2013) or self-reported higher levels of anhedonia (Bogdan and
Pizzagalli, 2006). Moreover, both acute and chronic stressors are reported to produce
hedonic blunting, predominantly in individuals with a family history of depression
(Berenbaum and Connelly, 1993; Al'absi et al., 2012). Conversely, pronounced
anhedonic symptoms are correlated with increased sensitivity to stress (Horan et al.,
2007). These observations indicate an interaction between brain stress and reward
systems in the emergence of depressive phenotypes.
Hypothalamic-pituitary-adrenal (HPA) axis
The hypothalamic-pituitary-adrenal (HPA) axis is an integral component of the body’s
homeostatic and stress response system. Exposure to either a physical or psychological
stressor facilitates synthesis and secretion of corticotrophin-releasing factor (CRF) from
the hypothalamus. CRF stimulates the secretion of adrenocorticotropic hormone (ACTH)
from the pituitary gland, which in turn triggers the adrenal glands to release
glucocorticoid hormones, commonly referred to as cortisol in humans and corticosterone
(CORT) in rodents (Sapolsky et al., 2000). Glucocorticoids mobilize the body’s energy
stores and regulate a variety of cardiovascular, metabolic, and immunological functions
to effectively prepare the body to respond to a stressor and facilitate recovery to
homeostasis (Kadmiel and Cidlowski, 2013). Over a longer time scale, glucocorticoids
regulate the expression of genes and promote memory formation, effects thought to
mediate adaptive modulations to the system for future events (de Kloet et al., 2005;
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Groeneweg et al., 2011).
Glucocorticoids enact their effects through molecular events that trigger genomic
and non-genomic mechanisms that involve the dual activation of intracellular
mineralocorticoid (MR) and glucocorticoid receptors (GR), collectively referred to as
corticosteroid receptors. Once diffused through the cellular membrane, glucocorticoids
bind to the receptor complex and translocate into the nucleus to act on DNA response
elements to activate gene transcription (Ringold, 1985). Alternatively, the receptor
complex can repress expression of genes by inhibiting other transcription factors from
binding to their target genes (De Bosscher et al., 2003). More recently, a non-classical
corticosteroid pathway involving membrane bound GRs and MRs has been shown to
mediate the rapid non-genomic mechanisms of stress response (Tasker et al., 2006).
Within the central nervous system, GRs and MRs differ in both their affinity for
glucocorticoids and regional pattern of expression. MRs exhibit a higher affinity for
glucocorticoids and regulate basal HPA tone, whereas GRs are only activated during
conditions involving high circulating levels of CORT and facilitate termination of the
stress response (De Kloet et al., 1998). GRs are widely distributed throughout the brain,
but exhibit high levels of expression in the hypothalamus and corticolimbic structures,
including the hippocampus, prefrontal cortex, and amygdala. MRs, on the other hand,
are less ubiquitous in the brain, but are highly expressed in the hippocampus (Young et
al., 2003; Joels et al., 2012). Elevated circulating levels of glucocorticoids serve as a
negative feedback signal to the HPA axis by binding to GRs at the level of the
hypothalamus and pituitary to inhibit further secretion of CRF and ACTH (Miller et al.,
1992). The HPA axis also receives strong regulatory inputs from the hippocampus.
Activation of corticosteroid receptors on hippocampal neurons signal for the termination
of HPA axis activity (Sapolsky et al., 1984; Jacobson and Sapolsky, 1991).
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Under normal conditions, glucocorticoids serve to facilitate the physiological
adaptations required to appropriately respond to stressors. Excessive activation of the
HPA axis, however, is thought to contribute to the onset of depressive symptoms. A
substantial proportion of MDD patients demonstrate signs of HPA axis dysfunction, as
evidenced by flattening of cortisol diurnal rhythms, augmented circulating concentrations
of cortisol and CRF (Nemeroff et al., 1984) and insensitivity to dexamethasone, an
exogenous steroid that suppresses cortisol in healthy controls (Holsboer et al., 1987).
Both the expression and function of GRs are significantly reduced in depressed
individuals (López et al., 1998; Pariante, 2004). Moreover, early-life stress exposure is
predictive of structural reductions in regions involved in regulation of the HPA axis
(Sahay and Hen, 2007; Treadway et al., 2009), indicating that HPA axis dysregulation in
depression likely occurs via diminished inhibitory feedback signals. Notably, MDD is
consistently associated with reductions in hippocampal volume (Campbell et al., 2004;
Videbech et al., 2004). In addition to its role in glucocorticoid inhibitory feedback
mechanisms, the hippocampus is also a key mediator of cognitive and emotional
processes. Thus, altered hippocampal neuronal activity may contribute to the
psychopathologies of depression.
Outside of the HPA axis, CRF-containing neurons and CRF receptors are widely
distributed throughout brain regions implicated in stress response (Swanson et al., 1983;
Sakanaka et al., 1987; Griebel and Holsboer, 2012), suggesting that CRF can act
directly at these regions independent of HPA axis activation (Koob et al., 1993;
Dautzenberg and Hauger, 2002). . The effects of CRF are mediated through activation of
two subfamilies of GPCRs, CRF-R1 and CRF-R2, though CRF shows greater binding
affinity for CRF-R1 (Dautzenberg and Hauger, 2002). Exogenous administration of CRF
mimics many of the behavioral and autonomic effects of acute stress exposure (Dunn
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and Berridge, 1987), and has been shown to induce depressive and anxiety-like
behaviors in rodents (Britton et al., 1982; Owens and Nemeroff, 1991; Liang et al., 1992;
Swiergiel et al., 2008). Notably, antagonism of CRF receptors attenuates many of the
affective behavioral responses to stress (Britton et al., 1986; Heinrichs et al., 1994; Bale
and Vale, 2004). Hypersecretion of CRF has been implemented in the onset of
depressive disorders. MDD patients exhibit elevated cerebrospinal fluid levels of CRF
(Nemeroff et al., 1984) and enhanced neuroendocrine response to the combined
dexamethasone/CRF test (Steckler et al., 1999) that is normalized after successful
antidepressant treatment (Heuser et al., 1998; Ising et al., 2005). Additionally, portmortem studies have revealed increased CRF expression and reduced binding in the
brains of depressed individuals. (Nemeroff et al., 1988; Purba et al., 1996).
Effects of Stress on Mesocorticolimbic Dopaminergic Pathways
Brain stress response systems interact with the midbrain DA system to produce complex
state-dependent responses to aversive stimuli (Cabib and Puglisi-Allegra, 2012).
Corticosteroid receptors and CRF receptors are expressed throughout the
mesocorticolimbic system, specifically in the prefrontal cortex, amygdala, NAc, and VTA
(Harfstrand et al., 1986; Van Pett et al., 2000; Dautzenberg and Hauger, 2002; Butts et
al., 2011; Hensleigh and Pritchard, 2013). CRF in the VTA reduces operant responding
for food reward and attenuates NAc DA release to food reward (Wanat et al., 2013).
Electrophysiological studies report inhibition of VTA DA neurons in response to stress
(Ungless et al., 2004), however distinct anatomical regions within the VTA have been
shown to contain DA neurons that differ in their molecular properties and response to
aversive versus rewarding stimuli. For example, DA neurons in the dorsal VTA are
inhibited by acute stress, whereas DA neurons in the ventral VTA are excited by
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aversive footshocks (Brischoux et al., 2008). Moreover, aversive stimuli selectively
modify synapses projecting to the mPFC, whereas rewarding stimuli modifies synapses
on DA cells projecting to NAc medial shell (Lammel et al., 2011). Additionally,
GABAergic neurons in the rostromedial tegmental nucleus (RMTg) project to VTA DA
neurons and are selectively activated in response to stress (Jhou et al., 2009). Thus,
aversive inputs from various brain regions implicated in stress response may converge
onto the RMTg to inhibit DA transmission in the NAc.
Several studies have reported robust DA release in the mPFC following acute
stress (Imperato et al., 1989) or acute administration of CORT (Piazza et al., 1996; Butts
et al., 2011). Chronic administration of exogenous CORT flattens glucocorticoid rhythm
and enhances basal and depolarization evoked DA release in the mPFC in a GRdependent manner (Ago et al., 2008; Minton et al., 2009). Mesocortical DA neurons
exert top-down control over striatal DA release (Deutch and Roth, 1990; King et al.,
1997; Ventura et al., 2002). Therefore, stress-induced potentiation of mPFC DA activity
may facilitate blunted DA release in mesolimbic pathways. Additionally, NAc
responsiveness to excitatory input from the mPFC has been shown to be regulated by
the hippocampus (O'Donnell and Grace, 1995). Hence, motivational states are likely
influenced by glucocorticoid-mediated alteration of hippocampal function. Interestingly,
stress-induced stimulation of mesoaccumbens DA release is associated with shortlasting or controllable aversive experiences (Abercrombie et al., 1989; Ventura et al.,
2002; Cabib and Puglisi-Allegra, 2012), whereas exposure to chronic or uncontrollable
stressors selectively activates the HPA axis (De Boer et al., 1989) and promotes
inhibition of mesoaccumbens DA (Puglisi-Allegra et al., 1991; Imperato et al., 1992;
Rossetti et al., 1993; Cabib and Puglisi-Allegra, 2012). Reduced mesoaccumbens DA
activity after chronic or uncontrollable stress is posited to contribute to coping failure and
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the development of behavioral despair (Cabib and Puglisi-Allegra, 2012). This holds
particular relevance for the etiology of psychiatric disease states seeing as exposure to
chronic stressors perceived as uncontrollable or unresolvable is more associated with
depressive behavior (Kendler et al., 2003).
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FIGURE 1.1

VTA-NAc reward circuit and HPA axis. A simplified schematic of the major
connections within the mesocorticolimbic dopamine system and hypothalamic-pituitaryadrenal axis. DA neurons originating from the VTA project to and innervate subcortical
and cortical regions. This pathway is further modulated by reciprocal glutamatergic and
GABAergic signaling. Exposure to stress activates secretion of CRF from the PVN,
which stimulates secretion of ACTH from the pituitary, which in turn triggers release of
CORT from the adrenals. CORT serves as a negative feedback signal at the level of the
pituitary and PVN. CRF and CORT act on brain regions that overlap with brain reward
circuitry to modulate dopamine response to both rewarding and aversive stimuli. ACTH,
adrenocorticotropic hormone; AMY, amygdala; CORT, corticosterone; CRF,
corticotropin-releasing factor; HIPP, hippocampus; LHb, lateral habenula; LDTg, lateral
dorsal tegmentum; NAc, nucleus accumbens; PFC, prefrontal cortex; PVN,
paraventricular nucleus of the hypothalamus; RMTg, rostromedial tegmentum; VTA,
ventral tegmental area.
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Opioid System
In addition to its well-established role in nociception and analgesia (Dickenson, 1991),
the opioid system is also highly implicated in the regulation of reward processing (Koob,
1992) and stress response (Bruchas et al., 2010). The endogenous opioid system is
composed of three principal families of G-protein coupled receptors (GPCRs), mu
(MOR), kappa (KOR), and delta (DOR), which interact with the peptides β-endorphin,
dynorphin, and enkephalin, respectively. Opioid receptors and their peptides are widely
expressed throughout the peripheral and central nervous system (Mansour et al., 1994;
Wittert et al., 1996). Within the brain, opioid receptors are primarily distributed in the
cortex and limbic system (Mansour et al., 1988). Opioid receptors localized to
mesocorticolimbic DA pathway are thought to mediate both the reinforcing properties of
rewards and the aversive properties of stressful experiences.
Activation of MORs expressed by GABAergic interneurons in the VTA disinhibit
the activation of DA neurons and facilitate DA release in the NAc (Johnson and North,
1992; Spanagel et al., 1992b), an essential molecular component of reward processing
(Contet et al., 2004). Studies in mice with genetic deletion of opioid receptors have
helped to establish that MORs mediate the reinforcing properties of addictive
substances, including morphine, nicotine, and ethanol (Matthes et al., 1996; Kieffer and
Gaveriaux-Ruff, 2002). Importantly, MORs also influence the processing of natural
rewards, as evidenced by reduced operant responding for both standard chow and
sucrose pellets in MOR knockout animals compared to wildtype (Papaleo et al., 2007).
Furthermore, activation of MORs in hedonic “hot-spots” within the NAc shell stimulates
positive orofacial reactions to food and increases consumption (Pecina and Berridge,
2005). The role of DORs in reward processing is not as clear, however deletion of DORs
or its endogenous ligand results in increased levels of anxiety and depressive-like
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behavior, suggesting that these receptors are more involved in mood-enhancing
processes (Konig et al., 1996; Filliol et al., 2000; Ragnauth et al., 2001).
In contrast, to the MOR and DOR, the KOR is more implicated in mediating the
aversive properties of stress or stimuli with negative emotional valence (McLaughlin et
al., 2003; McLaughlin et al., 2006a; McLaughlin et al., 2006b; Lutz and Kieffer, 2013).
Prolonged exposure to environmental stress can give rise to dysregulation of the
dynorphin-KOR modulatory system resulting in increased levels of dynorphins in
mesocorticolimbic regions (Shirayama et al., 2004; McLaughlin et al., 2006b). Activation
of KORs induce depressive-like and anxiety-like behaviors in rodents (Carlezon et al.,
2006; Van't Veer and Carlezon, 2013) and reduce DA release in key brain regions
involved in the processing of reward and motivation,(Svingos et al., 1999; Shirayama et
al., 2004; Flaisher-Grinberg et al., 2012). Notably, stimulation of KORs in the NAc region
decreases DA transmission, whereas administration of a KOR antagonist increases DA
transmission (Spanagel et al., 1992a). Moreover, infusion of a KOR agonist into the NAc
produces robust conditioned place aversion (Bals-Kubik et al., 1993). Facilitation of
stress-like effects by KOR activation is mediated in part by interactions with the
neuroendocrine system as evidenced by the finding that the behavioral and
neurochemical effects of environmental stress or exogenous CRF exposure are blocked
by treatment with KOR antagonists (McLaughlin et al., 2003; Land et al., 2008).
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FIGURE 1.2

The endogenous opioid system modulates DA transmission within the mesolimbic
pathway. KOR, kappa opioid receptor; MOR, mu opioid receptor. Adapted from Carroll
& Carlezon (2013).
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Rodent models of stress-induced depression
	
  
There is no singular animal model or paradigm that perfectly recapitulates the complex
symptomology of depression. However, converging lines of evidence support stressinduced molecular changes as a key mediator of the onset and progression of
depressive symptoms in humans. To that end, stress models of depressive behavior in
animals have utilized realistic and relevant inducing conditions to simulate critical
physiological components of the psychiatric condition (construct validity). Moreover,
these models have been shown to demonstrate face validity by producing behavioral
and physiological changes that parallel the symptom profile of depression. Finally,
animal models relevant to depression can be shown to demonstrate predictive validity by
responding appropriately to antidepressant drugs that are effective in humans).
Chronic Mild Stress (CMS)
The theoretical rationale for the CMS paradigm is derived from the clinical observation
that depressive episodes are often precipitated by an accumulation of life stressors, and
that stressors perceived as unpredictable or uncontrollable stressors are more
associated with the onset of depression (Kendler et al., 2003). The procedure, first
developed by Katz (1981), involved exposing subjects to a variety of severe stressors for
a period of three weeks. In the late 1980s, Willner and colleagues modified the paradigm
to avoid the use of severe stressors and instead utilize mild stressors (e.g. change of
cage mate, overnight illumination, food/water deprivation) presented in a semirandomized sequence to model unpredictability and prevent habituation to the stressors
(Willner et al., 1987). The procedure was originally targeted at modeling anhedonia, due
to the fact that chronically stressed animals consistently exhibited reduced preference
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for a sweetened solution, suggesting stress-induced modulation of reward sensitivity.
Additional studies have gone on to show that CMS exposure also elicits a wide variety of
behavioral and pathophysiological effects, including anxiogenic and depressive-like
behaviors, neurochemical changes and alterations in neuroplasticity (Willner, 2005).
Importantly, many of these effects have been shown to be reversed by antidepressant
treatment.
The many pathophysiological changes resulting from CMS provide a
comprehensive model of symptomologies that parallel the human condition when
exposed to stress and serve as an invaluable tool for the evaluation of neurobiological
mechanisms underlying affective behavior. The disadvantage of this model, however, is
the long duration and labor-intensive aspects of the procedure. Moreover, many
researchers have expressed frustration in the reproducibility of CMS-induced effects
between laboratories. Adoption of a standardized CMS protocol may help to increase
consistency in findings in the future.
Chronic CORT Treatment
The chronic CORT paradigm was developed as an etiologically relevant model of
depressive disorders characterized by hyper-activation of HPA axis activity. Indeed,
hypercortisolemia is frequently observed in MDD patients exhibit, which is thought to be
associated with some of the behavioral and cognitive deficits observed in depression. In
this paradigm exogenous CORT is delivered directly via oral administration, slow-release
CORT pellets, or serial injections for a period of 14 or more days. Along with elevating
circulating levels of CORT, chronic CORT treatment has been shown to reduce sucrose
preference and operant responding for rewards (Gourley and Taylor, 2009), increase
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behavioral despair as measured by immobility in the forced swim test and tailsuspension test (Gourley et al., 2008; David et al., 2009) and increase anxiety-like
behavior in the light-dark emergence task (Ardayfio and Kim, 2006). In addition, chronic
CORT treatment consistently reduces hippocampal cell proliferation and survival while
reducing expression of neurotrophins such as BDNF (Czeh et al., 2001; Bilsland et al.,
2006; Murray et al., 2008). Notably, many of the neurochemical and behavioral changes
produced by chronic CORT treatment are reversed by antidepressant treatment, thus
lending to the predictive validity of this model.
The advantage of chronic CORT treatment is several-fold. The procedure is
significantly less complex compared to the CMS protocol, and can easily be replicated
and confirmed by independent research groups. Whereas the CMS procedure may
produce varying degrees of CORT response in individual animals, the exogenous
administration strategy ensures that all animals are exposed to identical levels of CORT.
Although, it is possible that individual variations in HPA axis reactivity can influence the
behavioral and physiological consequences of exogenous CORT exposure. A limitation
of this method is that the HPA axis is only one of many systems that respond to stress.
Thus, the pathophysiological effects of CORT treatment alone are not necessarily
reflective of total exposure to physiological stress. There is also some variation between
laboratories in the way that CORT exposure is accomplished. Nonetheless, exogenous
administration of CORT enables investigation into how CORT specifically contributes to
the development of stress-induced changes in behavior and physiology	
  
Behavioral tests of anhedonia
Sucrose Preference Test
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The sucrose preference test is a measure of hedonic sensitivity to rewarding stimuli. In
this procedure, animals are given the choice of consuming either water or a
saccharin/sucrose solution. Non-stressed mice exhibit increased consumption of the
sweetened solution, whereas animals exposed to stress exhibit substantial reductions in
preference for the sweetened solution. This finding has long been hypothesized to model
reduced perception of rewards, and is thus often cited as an animal measure of
anhedonia. A hallmark of the CMS procedure is the demonstration of reduced sucrose
preference among stressed animals (Willner, 2005). Chronic treatment of stressed
animals with antidepressants restores sucrose preference, reflecting the way that
antidepressants have been shown to work in humans. Reduction in sucrose preference
after CMS is a controversial endpoint, however. Since stressed animals also experience
significant weight loss compared to non-stressed animals, sucrose intake data may be
adjusted to include weight differences between the two groups. In some instances,
differences in sucrose preference sometimes become insignificant when this is done
(Matthews et al., 1995; Forbes et al., 1996). However, other laboratories have shown
this finding to hold true irrespective of changes in body weight (Willner, 1997). Another
limitation of this test is that it doesn’t take into consideration the motivational aspects of
anhedonia, which appears to be the principal deficit in human populations. In fact, when
asked to rate the pleasantness of different concentrations of sucrose solutions, there is
no difference in hedonic value between depressed individuals and healthy controls
(Amsterdam et al., 1987; Berlin et al., 1998; Dichter et al., 2010). Regardless, the
sucrose preference test continues to be a widely used behavioral measure of anhedonia
in animals.
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Conditioning Paradigms
Approach motivation, the mobilization of energy by or toward a positively valenced
stimulus, is a fundamental component of reward-seeking behavior (Lewin, 1935).
Pavlovian conditioning theory posits that temporal pairing of a neutral conditioned
stimulus, such as an environmental cue, with an appetitive unconditioned stimulus, such
as food, can result in the acquisition of an approach response to the conditioned
stimulus in subsequent events. Appetitive reactions evoked by the conditioned stimulus
signal attribution of incentive salience, or “wanting”, thus maintaining learned behaviors
that facilitate acquisition of the rewarding or desired outcome. Alterations in conditioned
approach behavior may signal dysregulation of the neural mechanisms that translate
incentive learning into motivated behavioral output.
Operant Responding
Operant responding, also known as instrumental learning, is an oft-used measure of
motivational drive for rewarding stimuli in rodents. Rodents are trained to associate an
instrumental response (e.g. lever pressing) with a conditioned stimulus. Presentation of
the conditioned stimulus leads to an increase in instrumental responding. This paradigm
can be further adapted to utilize a progressive ration (PR) procedure in which the
experimenter progressively increases the number of lever presses required to obtain
each subsequent award (Hodos, 1961). The final ratio achieved by the animal before
discontinuing lever presses is referred to as the “break point” and is reflective of the
subject’s motivation or willingness to work for a reward. Operant paradigms provide a
more sensitive measure of motivational output compared to consummatory measures,
such as the sucrose preference test. It is important to note, however, that under a PR
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schedule animals periodically receive the reward as they successfully progress to the
next fixed ratio. The intermittent reinforcement of reward may contribute to sustained
levels of operant behavior, thus potentially obscuring the effects of experimental
manipulations on motivational drive in this paradigm.
Intracranial self-stimulation (ICSS) is an operant conditioning based behavioral
paradigm in which animals learn to self-deliver brief electrical pulses into specific brain
regions implicated in brain reward circuitry, most notably the lateral hypothalamus (LH)
(Olds and Olds, 1963) and VTA (Miliaressis et al., 1975). Dopaminergic fibers from the
VTA to the NAc pass through the LH and are innervated by peptidergic projections from
the LH that are thought to mediate rewarding responses to drugs of abuse (Fulton et al.,
2000; Kelley and Berridge, 2002; Kiefer and Wiedemann, 2004; Harris et al., 2005).
Acute administration of drugs of abuse lower ICSS thresholds (Vlachou and Markou,
2011), whereas CMS exposure increases ICSS thresholds, suggesting reduced
sensitivity to rewards reflective of an anhedonic state (Moreau et al., 1995). Similar to
traditional operant responding paradigms, ICSS allows for quantitative assessment of
behavioral output for rewarding stimuli. However, ICSS directly activates rewardprocessing systems while bypassing sensory modulatory inputs (e.g. palatability) that
may be involved in motivational salience.
Conditioned Place Preference (CPP)
The conditioned place preference paradigm utilizes Pavlovian conditioning to assess the
rewarding or aversive effects of a particular treatment or event (Tzschentke, 2007). In
this procedure, a drug or non-drug treatment is repeatedly paired with distinctive
environmental cues. Eventually the animal learns to associate the contextual cues with
the rewarding (or aversive) properties of the treatment and will choose to spend more (or
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less) time in the conditioned environment even in the absence of the original stimulus.
The CPP test is a powerful tool for investigating the neurobiological mechanisms
underlying the reinforcing properties of salient stimuli. However, because animals
passively receive the treatment, this paradigm may not fully address the effort-based
mechanisms associated with motivated behavioral output.
Novelty-induced hypophagia (NIH) test
The unconditioned suppression of feeding in a novel environment, commonly referred to
as hyponeophagia, is a well-documented phenomenon in rodents. Thus the noveltyinduced hypophagia (NIH) test taps into stress-induced changes in conditioned
approach behavior. In this paradigm animals are trained over a period of days to rapidly
approach and consume a highly palatable food reward in their home cage environment.
Once stable approach latencies for the food are established, animals are examined for
their appetitive and consummatory behavior in a brightly lit and differently scented novel
arena. Untreated animals consistently exhibit a robust increase in latency to approach
the food and reduced food consumed in the novel arena compared to the home cage.
Chronic treatment with antidepressant drugs reverses this effect. Interestingly, acute
treatment with an anxiolytic drug also reduced approach latency in this paradigm
(without altering home cage behavior), which led researchers to conclude that this
paradigm is a measure of anxiety-like behavior in rodents (Bodnoff et al., 1988; Bodnoff
et al., 1989; Dulawa and Hen, 2005). Alternatively, approach latency in the novel arena
may reflect altered motivational drive for rewarding stimuli. The distinct suppression of
approach behavior in the novel arena enables investigation into how aversive cues
contribute to diminished incentive salience for natural rewards.
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Goals of research
	
  
The overarching goals of this thesis research were to further elucidate the mechanisms
underlying stress-induced changes in motivational drive and in the process identify
potential pharmacological targets for the prevention or reversal of affective behavior. The
majority of studies examining the neurobiological underpinnings of motivated behavior
for natural rewards has been conducted in rats and has at times conflated hedonic
processes and motivational output in their assessment of anhedonic behavior. In this
thesis work we employed a single conditioned approach behavioral paradigm in mice in
which “liking” (amount of food consumed) and “wanting” (latency to approach the food)
behaviors could de easily dissociated so as to simultaneously measure the motivational
aspects and neurochemical substrates underlying incentive salience for a salient
stimulus. Once characterizing the core neurochemical phenotype associated with stable
approach behavior, we uncovered the effects of stress on these same neural processes,
thus establishing a unique role for NAc DA in the onset and maintenance of incentive
behavior in mice. Next, using the same behavioral paradigm we identified distinct
pharmacological targets within the brain opioid system as potential mediators of
conditioned approach behavior under stress. Lastly, we sought to address the role of
stress hormones in mediating behavioral response to the selective serotonin reuptake
inhibitor (SSRI) fluoxetine in the NIH paradigm. Together, these findings help to broaden
our understanding of the mechanisms underlying anhedonic behavior in stress related
psychiatric disorders.
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Abstract
Anhedonia is a hallmark symptom of several psychiatric disorders, including depression,
schizophrenia and post-traumatic stress disorder. Given the frequent presentation of
anhedonia in stress-related psychiatric disorders, we assessed the effects of stress on
the motivational and neurochemical correlates underlying conditioned approach behavior
for palatable food in the mouse. The effect of palatable food exposure was measured on
dopamine release in the nucleus accumbens (NAc), a region known to play a prominent
role in food reward behavior in awake freely moving C57BL/6J mice using in vivo
microdialysis. Animals trained to consume food in a familiar environment exhibited a
significant 30% elevation in NAc dopamine release coincident with the presentation of
food. This effect was not seen in animals that consumed the food in an unfamiliar
environment or interacted with the food reward for the first time and was region specific.
Presentation of an acute stressor (bright light and novel scent) during food exposure
blocked dopamine release and delayed approach behavior in response to the food
reward in trained animals. These effects were reversed in animals pretreated with
buprenorphine, a mixed opioid drug shown previously to produce antidepressant-like
and anxiolytic effects. Together, these data indicate that exposure to mild stress
reduces incentive drive to approach palatable food via alterations in NAc dopamine
responsiveness to the food reward. Moreover, they implicate the brain opioid system as
a potential pharmacological target for treatment of anhedonia
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Introduction
Anhedonia, the lost of interest or pleasure in typically enjoyable or rewarding activities, is
a hallmark symptom of several psychiatric disorders including depression, schizophrenia
and post-traumatic stress disorder. Although trait anhedonia encompasses both
consummatory and motivational components, clinical studies indicate that the major
deficit lies in motivational output as opposed to processing of hedonic value (Burbridge
and Barch, 2007; Sherdell et al., 2012; Argyropoulos and Nutt, 2013). Dopamine (DA)
neurotransmission has long been known to be involved in the processing of reward and
motivation, and more recently shown to modulate depressive-like behavior in rodents
(Chaudhury et al., 2013; Tye et al., 2013). Yet, the manner in which altered DA activity
influences changes in behavior is still not well understood.
The brain’s reward system is composed in part of mesolimbic DA neurons
originating in the ventral tegmental area (VTA) that project to and innervate several
limbic structures including the nucleus accumbens (NAc). Dopaminergic innervation of
the NAc is thought to play a critical role in mediating the reinforcing properties of both
drugs of abuse and natural rewards. Studies conducted largely in rats have measured
phasic increases in extracellular concentrations of DA in the NAc in response to both
initial consumption of a palatable food reward and the instrumental responding for food
(Bassareo and Di Chiara, 1997; Ahn and Phillips, 2007). On the other hand, depletion or
inhibition of DA activity in the NAc reduces goal-directed behavior towards food, but
does not diminish hedonic reactions to food (Berridge, 2007, 2012a). Thus,
dopaminergic signaling in the NAc is likely involved in both initiating unconditioned
appetitive behavioral responses and eliciting cue-triggered incentive salience (Berridge
and Robinson, 1998; Cardinal et al., 2002; Parkinson et al., 2002; Cone et al., 2016).
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However, very little work has been done in evaluating the relationship between NAc DA
reactivity to food stimuli and approach behavior in other species, such as mice, which
exhibit different approach and appetitive behaviors to novel and familiar foods.
Given the frequent presentation of anhedonia in stress-related psychiatric
disorders, exposure to stress may contribute to the dysregulation of reward circuitry. The
endogenous opioid system has been implicated in mediating the aversive properties of
stress (McLaughlin et al., 2003; McLaughlin et al., 2006b; Lutz and Kieffer, 2013b) and
has been shown to either facilitate or reduce DA release in key brain regions involved in
processing of reward and motivation, including the NAc (Svingos et al., 1999; Shirayama
et al., 2004; Bruchas et al., 2009; Flaisher-Grinberg et al., 2012a). Recent studies in
animals have revealed promising effects of opioid drugs, such as buprenorphine (BPN),
in ameliorating anxiety and depressive like behaviors induced by stress (Almatroudi et
al., 2015; Browne et al., 2015; Falcon et al., 2015; Falcon et al., 2016b). Moreover,
clinical trials have shown BPN to have therapeutic effects in treatment-resistant human
populations (Bodkin et al., 1995a; Nyhuis et al., 2008; Ehrich et al., 2014).
The goal of the present study was to use a single behavioral paradigm in mice to
simultaneously measure the motivational aspects and neurochemical substrates
underlying approach behavior for palatable food reward. Changes in extracellular DA
levels in the NAc and behavior were measured during the presentation of palatable food
to non-deprived C57BL/6 mice using in vivo microdialysis. Comparison of the effects of
conditioned versus unconditioned food stimuli on NAc DA release and approach
behavior established that prior exposure to food reward was necessary to produce foodcued DA reactivity in the NAc and that this response reflected both anticipatory and
consummatory signals. DA levels in the striatum were unaffected. Once the core
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neurochemical phenotype associated with stable approach behavior was established,
we demonstrated that exposure to an acute stressor during food presentation inhibited
the NAc DA response to a conditioned food stimulus and reduced motivational salience
for the reward, as measured by increased latency to approach. Lastly, we showed that
pretreatment with the mixed-opioid drug BPN prevented both the neurochemical and
behavioral effects of stress in this paradigm.
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Materials and Methods
	
  
Animals
Male C57BL/6 J mice, 7-8 weeks old upon arrival, were purchased from Jackson
Laboratories (Bar Harbor, ME). Mice were housed in pairs in polycarbonate cages and
maintained under a 12 hour light-dark cycle (lights on at 0700 hours) in a temperature
(22 °C)- and humidity-controlled environment. Chow and water were available ad libitum.
All experiments were approved by the Institutional Animal Care and Use Committee at
the University of Pennsylvania.
Drugs
Buprenorphine hydrochloride (Sigma, St. Louis, MO) was dissolved in distilled water and
injected intraperitoneally (i.p.). The dose was calculated according to the base weight of
the drug and administered in a volume of 10 ml/kg.
Surgery
Microdialysis probes were custom-made and surgically implanted in mice as described
previously (Knobelman et al., 2001). Under isoflurane anesthesia, the probe was
implanted in the nucleus accumbens [ +1.2 mm anteroposterior (AP), ±0.5 mm
mediolateral (ML) from bregma, −4.5 mm dorsoventral (DV) from dura] or dorsal
striatum (+1.0 mm AP, ±1.7 mm ML fro bregma, −4.5 mm DV from dura) (Franklin and
Paxinos, 1997) using a stereotaxic instrument. BPN treated mice were injected with
drug immediately after completion of surgery while still anesthetized. Untreated animals
received no injection. Following surgery, the mice were placed into a 21.5 cm high, clear
polycarbonate cylindrical in vivo microdialysis chamber with a counterbalance arm
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holding a liquid swivel (Instech Laboratories, Plymouth Meeting, PA) and allowed to
recover overnight with the pump flow rate set to 0.9 µl/min. For testing the flow rate was
set to 2.2 µl/min. Dialysate samples were collected into polypropylene microcentrifuge
vials and stored at −80 °C until analyzed for dopamine as described previously (Andrews
and Lucki, 2001) using a Shimadzu Prominence HPLC system (including a LC-20 AD
pump and Sil-20 AC refrigerated microsampler) using a Unijet microbore column (3 µM
ODS/ 100 × 1 mm) coupled with an Antec Decade II electrochemical detector. DA levels
were identified by comparing their elution times with those of reference standards and
quantified from their respective peak heights using a linear regression analysis of the
peak heights obtained from a series of reference standards.
Experimental procedures
Mice were trained to consume three (~1.4g) Reese’s peanut butter chips (The Hershey
Company, Hershey, PA) presented in a small, clear petri dish in a home cage
environment in daily 15-minute sessions. Opaque, black, plastic dividers were placed
inside each home cage to separate the mice during training sessions. Mice were allowed
to habituate to the dividers for 1 hour before the start of the training session. Sessions
continued until animals approached the food reward in less than 30 seconds for three
consecutive days. Mice assigned to the “test cage” trained group received five additional
training sessions in the microdialysis chamber. Mice assigned to the “home cage”
trained group underwent surgery after meeting criteria in the home cage and were tested
in the microdialysis procedure without prior food exposure in the microdialysis chamber.
Mice assigned to the “no training” group were naïve to the food reward and received no
training prior to surgery and testing. All animals were tested in the microdialysis
chamber.
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Microdialysis experiments started 17–20 hours after surgery. The pump flow rate
was increased to 2.2 µl/min two hours prior to testing. Baseline dialysate samples were
collected at five-minute intervals starting one hour prior to food exposure. The final three
samples were used to establish a baseline value before food exposure. During food
exposure, a small clear petri dish with three peanut butter chips was placed in the
microdialysis chamber for fifteen minutes and 3 samples were collected. Three
additional samples were collected after the food dish had been removed. At the
completion of the experiment, the mice were sacrificed and their brains were removed,
placed in cold isopentane, and frozen at −80 °C. The brains were then sectioned (35
µm) with a refrigerated cryostat and the tissue examined for the location of the dialysis
probe.
Behavioral recordings
Mice were evaluated for their responses to food presentation in the microdialysis
chamber. The latency to eat the peanut butter chips and the amount consumed during
the 15-minute feeding period was live recorded for each animal. Mice were also
monitored for defensive burying (aggressive shoveling movement of bedding material
with forepaws), rearing (standing on hindpaws), grooming (nose/face/body washing),
and idle (absence of active moments) behavior before, during, and after food
presentation. For each behavioral category, mice received a score of either “1” if they
engaged in the behavior within the 5 minute sampling time or “0” if they did not. The
scores were averaged among animals in each group for each time point, thereby
reflecting the proportion of animals engaging in a particular behavior at a given time.
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Data analysis
One-way and two-way ANOVA were performed to examine the significance of
differences between experimental groups. Significant overall main effects were followed
by Dunnett’s or Holm-Sidak’s multiple comparisons test where appropriate. Microdialysis
data were expressed as a percentage of baseline values determined by the mean of
three samples collected immediately before food presentation. A repeated measures
two-way ANOVA was used to compare variations in DA levels within experimental
groups and significant differences were followed by Dunnett’s test. Variations in DA
levels between groups were compared at individual time points using Tukey’s test. For
all tests, p<0.05 was considered statistically significant. Data are expressed as mean
±SEM.
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Results
	
  
The effects of training experience on DA response and approach behavior to palatable
food
To determine whether familiarity with the food reward and feeding environment impacts
DA response and approach behavior to palatable food in C57BL/6J mice, we first
evaluated the effects of training experience on NAc DA reactivity and latency to
approach and consume the food. Repeated-measures two-way ANOVA revealed a
significant effect of training experience [F(2, 15)=9.884, p=0.002] and an interaction
between training experience and time [F(16, 120) = 2.713, p=0.001] on extracellular DA
levels in response to the food presentation. Multiple comparisons indicated that food
presentation significantly increased extracellular DA levels (~30%) in the NAc of animals
exposed to food in the test cage (p<0.05). DA levels remained high after the food was
removed. This response was attenuated in animals allowed to consume the food in
feeding cages but not in the test cage (home cage trained animals) and returned to
baseline levels after removal of the food. Animals that were naïve to the peanut butter
chips did not demonstrate significant variation of DA levels during or after presentation of
the food (Figure 2.1A).
Differing approach latencies between groups [F(2,15]=84.98, p <0.001] paralleled
the association between DA levels and food presentation (Figure 2.1B). Animals
interacting with the food reward for the first time had a significantly higher approach
latency compared to test cage and home trained animals (p <0.001). Similarly, the
amount of food consumed differed between groups [F(2,15)=14.92, p=0.003]. As
illustrated in Figure 2.1C, test cage trained and home cage trained animals consumed
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more of the peanut butter chips compared to untrained animals (p < 0.01).
Determination of a behavioral profile, by measuring burying, rearing, grooming,
and idle behavior before, during, and after food presentation, provided additional
information on the differential effects of training experience. Animals with no previous
experience with the food reward showed significantly more burying behavior during food
presentation compared to test cage and home cage trained animals. A two-way ANOVA
revealed a significant main effect of time [F(8,120)=8.658, p<0.0001] and an interaction
between training experience and time [F(16, 120)=2.401, p=0.016] on the amount of
burying behavior (Figure 2.2A). A significant main effect of time was also observed for
rearing [F(8, 120)=4.074, p<0.003] (Figure 2.2B) and grooming [F(8,120)=2.562,
p<0.013] (Figure 2.2C) behaviors. Animals from all groups exhibited more rearing and
grooming behavior following food presentation. Analysis of the time spent idle showed a
significant main effect of time F(8,120)=12.05, p<0.0001] and an interaction between
groups F(16,120)=3.072, p<0.0002]. Home cage trained and animals without training
spent more time idle prior to food exposure compared to test cage trained animals
(Figure 2.2D). Moreover, untrained animals spent more time idle during food
presentation compared to test cage and home cage trained animals.
NAc DA is responsive to anticipatory and consummatory cues for palatable food
Having demonstrated that mice trained to feed in the test cage exhibit DA reactivity to
food exposure, we next sought to address whether the NAc DA response is an appetitive
signal or dependent on consummation of the food reward. To test this, we presented test
cage trained animals with empty petri dishes (in which the peanut butter chips were
previously stored) while sampling from the NAc (Figure 2.3A). In the absence of food, we
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observed a 40% elevation in DA in response to presentation of the food dish
F(8,32)=5.184, p=0.003].
NAc DA response to palatable food is not reflective of generalized striatal activity
To examine the regional specificity of the food-induced DA response, a separate cohort
of test cage trained animals was implanted with microdialysis probes in the dorsal
striatum. As seen in Figure 2.3B, food presentation had no effect on extracellular DA
release in this region F(8,24)= 1.663, p=0.160], although these animals exhibited similar
approach latencies and food consumption to animals who received probe implants in the
NAc (data not shown).
BPN prevents effects of stress on NAc DA response and approach behavior
The next experiment measured how stress exposure influences the NAc DA response to
a familiar food reward and approach behavior. Repeated measures ANOVA revealed a
significant effect of treatment [F(2,19)=9.848, p=0.001], time [F(8,152)=3.454, p=0.001],
and an interaction [F(16, 152)=2.541, p=0.002]. Animals exposed to acute stress, a
bright light and novel scent during food presentation, exhibited no change in extracellular
DA in response to the food reward (Figure 2.4A). In contrast, animals treated with BPN
24 hours prior to testing showed restored DA response to the palatable food reward.
Exposure to stress also increased latency to approach the food compared to
unstressed animals (Figure 4B). A one way ANOVA also revealed a significant effect of
stress on latency to approach the food reward [F(2,19)=4.735, p=0.021]. This effect was
reversed in animals pretreated with BPN. Interestingly, there was no significant
difference between groups in amount of food consumed [F(2,19)=0.040, p=0.961]
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(Figure 2.4C).
Examination of the behavioral profile indicated differences in burying and rearing
behaviors before, during, and after food presentation between groups. There was a
significant main effect of time on burying behavior [F(8,152)=6.068, p=0.001] (Figure
2.5A). For rearing behavior, there was a significant main effect of time [F(8,152)=6.958,
p=0.001] and an interaction [F(16, 152)=2.242, p=0.006]. Untreated animals exposed to
the stressor exhibited increased rearing during and after the feeding period compared to
unstressed animals (Figure 2.5B). There were also significant main effects of time on
grooming [F(8,152)=2.816, p=0.006] and idle [F(8,152)=6.848, p=0.001] behavior.
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Discussion
The present study is the first to establish in mice that repeated exposure to palatable
food elicits DA efflux in the NAc, and that the major component of the DA response is
associated with the conditioned incentive salient effects, as measured by the decreased
latency to approach the food. Because mice were not food deprived prior to testing,
approach behavior likely represents motivational “wanting” as opposed to a homeostatic
drive to feed. Presentation of the palatable food in an unfamiliar feeding environment, or
to mice that were naïve to the food reward, failed to elicit a NAc DA response. The DA
response was limited to the NAc and did not occur in the striatum. Altogether, these
findings indicate a critical role for NAc DA transmission as a substrate for facilitating the
emergence and maintenance of motivated behavioral output for food reward.
Furthermore, we showed that exposure to stressful stimuli during food presentation
diminishes the NAc DA response and increases approach latency to the conditioned
food stimulus. Remarkably, pretreatment with BPN 24 hours prior to testing blocked the
effects of stress on NAc DA reactivity and restored approach behavior for the food,
suggesting a role for opioid systems in mitigating the aversive effects of stress on
incentive salience for natural rewards.
There is an expansive body of literature implicating a role for DA in mediating
reward-seeking behavior for natural reinforcers, the majority of which have been
conducted in rats (Ikemoto and Panksepp, 1999). Although the present study design is
similar in some respects to those done in rats, our findings reveal key disparities in the
correlational relationship between NAc DA response to food and incentive behavior.
Notably, in rats, consumption of a novel food, but not a familiar food, stimulates DA
release in the NAc (Bassareo and Di Chiara, 1997; Gambarana et al., 2003). Thus, DA
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response to a novel food in rats likely serves as a learning cue that is subject to
habituation following repeated exposure. In contrast, we show that repeated exposure to
a food stimulus in a familiar feeding environment is necessary to induce a DA response
in the mouse NAc. Furthermore naïve mice exhibited more burying and idleness during
food presentation, suggesting that the animals found the novel food aversive rather than
appealing. Overall, these findings highlight the importance of environmental context in
the emergence of conditioned neurochemical and behavioral responses to rewards in
the mouse.
In rats, stimuli that predict a reward consistently promote DA release in the NAc,
whereas the DA response to physical consumption of the reward is variable (Cenci et al.,
1992; Salamone et al., 1994; Martel and Fantino, 1996; Hajnal and Norgren, 2001). In
the current study, test cage trained mice presented with the predictive stimulus (empty
food dish) exhibited a sharp rise in NAc DA efflux that rapidly returned to baseline.
However, in animals allowed to feed DA efflux persisted throughout food presentation
and after removal of the food. Therefore, NAc DA transmission in mice is responsive to
both anticipatory and consummatory cues.
The chronic mild stress (CMS) paradigm has repeatedly been shown to reduce
preference for a sucrose solution in rodents. (Papp et al., 1991; Willner et al., 1992;
Rygula et al., 2005; Willner, 2005). Optogenetic activation of VTA DA neurons restores
sucrose preference in mice after CMS exposure, implicating a role for the mesolimbic
DA system in mediating stress-induced changes in reward processing (Tye et al., 2013).
Although reduced sucrose preference is often cited as an anhedonic effect, the
translational value of this test is limited in that it more closely models changes in hedonic
value of a reward, which is not typically observed in anhedonic patients (Berlin et al.,
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1998; Dichter et al., 2010). CMS has also been shown to blunt NAc DA reactivity to
palatable food in rats (Di Chiara and Tanda, 1997; Di Chiara et al., 1999; Gambarana et
al., 2003). However, because stress did not alter approach behavior or food
consumption in these studies, it is difficult to interpret how diminished NAc DA response
influenced motivational salience.
In the present study we adapted a hyponeophagia-based paradigm to model how
stress affects the neurochemical underpinnings of motivational drive. The suppression of
feeding in a novel environment is a well-documented phenomenon in rodents and often
used to assess emotionality and anxiety. Chronic treatment with antidepressants or
acute treatment with anxiolytic drugs reduces approach latencies for food in a novel
environment, suggesting a restoration of incentive salience for the food (Bodnoff et al.,
1988; Bodnoff et al., 1989; Dulawa and Hen, 2005). We hypothesized that reduction in
NAc DA transmission in response to food presentation by a stressful or unfamiliar
environment may be associated with changes in approach behavior, and possibly serve
as a neurochemical substrate of a component of anhedonia. Indeed, presentation of a
bright light and novel scent during food exposure blunted NAc DA reactivity to the
conditioned food stimulus and significantly increased the time to consume the food.
Interestingly, the amount of food consumed was not altered in animals exposed to the
novel stimuli, signifying that stress specifically alters neurocircuitry associated with
motivational drive as opposed to hedonic value. These findings are in line with the
incentive salience theory which postulates that hedonic “liking” and motivational
“wanting” are independent psychological processes controlled by different neural
mechanisms (Berridge, 2007; Wise, 2008a). Specifically, the theory posits a role for DA
in mediating appetitive goal-directed behavior. Hence, anhedonic behavior may derive
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from alterations in dopaminergic activity that would normally promote motivational
salience.
The brain opioid system has long been known to play a role in mediating reward
seeing-behavior. Activation of mu-opioid receptors (MORs) in the ventral tegmental area
results in increased DA release in the NAc, an effect that is associated with increased
intake of palatable food (Spanagel et al., 1992; Zhang et al., 2003; Pecina and Berridge,
2005; Katsuura and Taha, 2010; Murray et al., 2014). In contrast, activation of kappa
opioid receptors (KORs) in the NAc inhibits DA neurotransmission and induces
prodepressive behaviors in rodents (Maisonneuve et al., 1994; McLaughlin et al.,
2006b). Moreover, exposure to stress increases levels of dynorphins (the endogenous
ligand of KORs) in limbic regions. Consequently, increased activation of KOR is a
potential mechanism in which stress diminishes DA reactivity to food reward. It is
important to note, however, that physical stressors can also increase DA efflux in the
NAc (Thierry et al., 1976; Abercrombie et al., 1989; Imperato et al., 1992; Kalivas and
Duffy, 1995a). Thus, environmental stress may differentially affect NAc DA
neurotransmission in response to expected rewards.
BPN is a mixed-pharmacology opiate drug, with potent activity as a partial
agonist at the mu-opioid receptor (MOR) and antagonist at kappa-opioid receptors
(KOR) (Lutfy and Cowan, 2004; Cowan, 2007). Our laboratory and others have shown
that low doses of BPN treatment reduce latency to approach palatable food in a novel
environment (Almatroudi et al., 2015; Falcon et al., 2015). In the present study BPN was
effective in restoring approach behavior and NAc DA reactivity to food in animals
exposed to an acute stressor. Animals were tested 24 hours after BPN administration, a
time at which the drug is no longer activating MOR, but may still have antagonist activity
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at KOR (Paronis and Bergman, 2011). Moreover, the dose of BPN used in the current
study does not alter extracellular DA levels in the NAc when injected 1 hour prior to
sampling (Falcon et al., 2015); therefore, it is unlikely that DA levels would be altered 24
hours later. Thus, BPN’s effect in this paradigm may be mediated by inhibition of KORinduced reduction in NAc DA, though additional studies are needed to confirm this.
DA neurotransmission in the NAc is only one facet of the complex and
interconnected circuitries that govern the brain reward system. Dopaminergic VTA
neurons also innervate the medial prefrontal cortex (mPFC) and basolateral amygdala
(BLA), structures known to mediate the processing of both rewarding and aversive
stimuli. The mPFC and BLA also send dense glutamatergic inputs to NAc DA terminals,
which can synaptically facilitate or depress DA efflux in the NAc (Floresco et al., 1998;
Jackson and Moghaddam, 2001). Moreover, DA transmission in the NAc has been
shown to interact with corticolimbic glutamate signaling to facilitate the emergence of
incentive salience for a food reward (Faure et al., 2008). Additional studies are needed
to determine how stress-induced changes in glutamate transmission modulate DAmediated incentive salience.
In conclusion, our findings with a mouse model measuring the motivational
aspects and neurochemical substrates underlying approach behavior for palatable food
reward suggest a unique role of NAc DA transmission in establishing and mediating
incentive salience for a palatable food reward in mice. Moreover, we show that exposure
to an acute stressor is sufficient to alter NAc DA responsiveness to a food reward, which
in turn diminishes approach behavior. The ability of BPN to prevent changes in
neurotransmission and behavior caused by stress exposure supports the opioid system
as a potential target for the development of novel therapeutic treatments of anhedonia
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and emotional dysfunction.
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FIGURE 2.1

Effects of training experience on NAc DA response and approach behavior to
palatable food. A) NAc DA response to food presentation in test cage trained (n=7),
home cage trained (n=6), and naïve animals (n=5). Black bar denotes duration of food
exposure. Test cage trained animals were the only group to exhibit a significant change
from baseline in DA levels in response to the food reward. The asterisk denotes
significant differences compared to baseline values within the test cage trained group
(*p<0.05, ***p<0.001). The symbol # denotes significant differences in DA release
between test cage trained and home cage trained animals (#p<0.05). The symbol &
denotes significant differences in DA release between test cage trained and naïve
animals (&p<0.05). B) Naïve animals took longer to approach the food and C)
consumed less food compared to test cage trained animals. The asterisk denotes a
significant difference compared to test cage trained animals (***p<0.001, ****p<0.0001).
Data is depicted as mean ± SEM.
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FIGURE 2.2

Effects of training experience on behavioral profile. Time course of behavioral
profiles of test cage trained (n=7), home cage trained (n=6), and naïve animals (n=5).
Behavior was scored in blocks of 5 minutes and measured before, during, and after food
exposure. Animals were evaluated for changes in A) burying, B) rearing, C) grooming
and D) idle behavior. Naïve animals exhibited more burying behavior and idle behavior
during food presentation. The asterisk denotes a significant difference compared to test
cage trained animals. (*p<0.05). Data is depicted as mean ± SEM.
64	
  
	
  

	
  
FIGURE 2.3

DA response to conditioned cues for food reward and effects of food exposure on
general striatal activity. Black bar denotes duration of conditioned cue or food
exposure. A) NAc DA response to presentation of a conditioned cue (empty food plate)
in in test cage trained animals exposed to an empty food plate (n=5). Exposure to the
empty plate significantly increased NAc DA levels from baseline. The asterisk denotes
significant differences compared to baseline values (**p<0.01). B) Dorsal striatum DA
response to food presentation in test cage trained animals (n=4). Food presentation did
not alter DA transmission in the dorsal striatum. Data is depicted as mean ± SEM.
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FIGURE 2.4

Effects of stress exposure and BPN treatment on NAc DA response and approach
behavior to palatable food. A) NAc DA response to food presentation in test cage
trained animals exposed to a stressor (bright light and novel vanilla scent) during food
presentation (n=8), and test cage trained animals treated with BPN and exposed to a
stressor during food presentation (n=7). Black bar denotes duration of food and stress
exposure. BPN treatment prevented stress-induced inhibition of NAc DA response to
food. The asterisk denotes significant differences compared to baseline values within the
BPN treated group (*p<0.05). The symbol # denotes significant differences in DA release
between test cage trained animals and untreated test cage trained animals exposed to
the stressor (##p<0.01, ###p<0.001, ####p<0.0001, analysis includes data from Figure
2.1A). The symbol & denotes significant differences in DA release between untreated
and BPN treated test cage trained animals exposed to the stressor (&p<0.05,
&&p<0.01). B) Untreated test cage trained animals exposed to the stressor took longer
to approach the food compared to non-stressed test cage trained animals. Approach
latency was restored to control values in BPN treated animals. The asterisk denotes a
significant difference compared to test cage trained animals (*p<0.05, analysis includes
data from Figure 2.1B). The symbol # denotes a significant difference between
untreated and BPN treated test cage trained animals exposed to the stressor (#p<0.05).
C) There was no significant effect of group condition on amount of food consumed. Data
is depicted as mean ± SEM.
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FIGURE 2.5

Effects of stress exposure and BPN pretreatment on behavioral profile. Time
course of behavioral profiles of test cage trained animals exposed to a stressor during
food presentation (n=8), and test cage trained animals treated with BPN and exposed to
a stressor during food presentation (n=7). Behavior was scored in blocks of 5 minutes
and measured before, during, and after food exposure. Animals were evaluated for
changes in A) burying, B) rearing, C) grooming and D) idle behavior. Untreated animals
exposed to stress displayed more rearing behavior during food presentation compared
to non-stressed test cage trained animals. The asterisk denotes a significant difference
compared to test cage trained animals (*p<0.05, analysis includes data from Figure 2.2).
Data is depicted as mean ± SEM.
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Abstract
Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa
(KOR) opioid receptors, has been shown to produce behavioral responses in rodents
that are similar to those of antidepressant and anxiolytic drugs. Recent studies have
identified KORs as the primary mediator of BPN’s effects in rodent models of
depressive-like behavior. However, the role of MORs in BPN’s behavioral effects has not
been as well explored. The current studies investigated the role of MORs in mediating
conditioned approach behavior in the novelty-induced hypophagia (NIH) test, a
behavioral measure previously shown to be sensitive to BPN treatment. The effects of
BPN were evaluated in the NIH test 24 hr post-administration in mice with genetic
deletion of MOR (Oprm1-/-) or KORs (Oprk1-/-), or after pharmacological blockade with
the non-selective opioid receptor antagonist naltrexone. Behavioral responses to BPN in
the NIH test were blocked in Oprm1-/- mice, but not Oprk1-/- mice. To further elucidate
the opioidergic mechanisms underlying behavioral response in the NIH paradigm,
animals were treated with the MOR agonist morphine, the KOR antagonist nor-BNI, or
the selective MOR antagonist cyprodime and assessed for approach behavior in the
novel arena. The antagonist cyprodime significantly reduced approach latency, whereas
morphine and nor-BNI were both ineffective. Moreover, antinociceptive studies with
morphine confirmed MOR antagonist effects of cyprodime and revealed MOR antagonist
properties of BPN 24 hr post-administration. Interestingly, the combined treatment of
naltrexone with BPN did not block BPN’s ability to reduce approach latency in the novel
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arena. Altogether, these data support modulation of MOR activity as a key component of
BPN’s antidepressant-like effects in the NIH paradigm.
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Introduction
Opioid receptors and their endogenous ligands are important modulators of neural
pathways involved in the regulation of mood and emotional states (Lutz and Kieffer,
2013a). The kappa opioid receptor (KOR) in particular is thought to contribute to the
etiology of depression and anxiety (Bruchas et al., 2010). Exposure to stress increases
expression of dynorphin, a neuropeptide that acts primarily at KORs (Shirayama et al.,
2004). Activation of KORs by dynorphin or a KOR agonist has been shown to elicit
dysphoria and depressive-like behavior in rodents (Carlezon et al., 2006; McLaughlin et
al., 2006c; McLaughlin et al., 2006a), whereas treatment with a selective KOR
antagonist mitigates stress-induced affective behavior (Mague et al., 2003; McLaughlin
et al., 2003; Carr et al., 2010). These preclinical findings have lent support to
pharmacological modulation of the opioid system as a potential target for the
development of novel antidepressants. Buprenorphine (BPN), a mixed-opioid drug, has
emerged as a promising new candidate as an antidepressant drug. Clinical studies have
shown low doses of BPN to be effective in alleviating depressive symptoms in treatmentresistant patients and reducing suicidal ideation in severely suicidal patients (Bodkin et
al., 1995b; Nyhuis et al., 2008; Yovell et al., 2015). Most notably, mood-elevating effects
were observed within a couple weeks of treatment, in stark contrast to first-line
treatments that often take 4-6 weeks to enhance mood.
BPN is a high affinity partial agonist at the MOR and an antagonist at the KOR.
Preclinical studies have identified KOR antagonism as a potential mediator of BPN’s
therapeutic effects in the FST (Almatroudi et al., 2015; Falcon et al., 2015). Whether
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BPN’s effects at the MOR significantly contribute to its effects on other behavioral tests
for antidepressant activity is not as well understood. Our laboratory has previously
shown that a single administration of low dose BPN ameliorates stress-induced
suppression of approach behavior for palatable food when tested 24 h postadministration (Falcon et al., 2015). The goal of the present study was to investigate the
role of individual opioid receptors in mediating BPN’s restoration of conditioned
approach behavior in the novelty-induced hypophagia test. To that end, we employed
two approaches, genetic deletion and selective pharmacological modulation of opioid
receptors, to distinguish the MOR from the KOR as the primary mediator of BPN’s
effects in this paradigm. The results of this study show that BPN was effective in
reducing approach latency in the novel arena in Oprk1-/- mice but not Oprm1-/- mice.
Administration of the selective MOR antagonist cyprodime, but not the MOR agonist
morphine or KOR antagonist nor-BNI, replicated the effects of BPN in the NIH test.
Moreover, BPN’s effects were not blocked by combination treatment with naltrexone.
These studies suggest a role for the MOR in mediating the antidepressant-like response
of BPN in the NIH test as a behavioral measure of motivational conflict.

78	
  
	
  

Materials and Methods
Animals
Male C57BL/6J mice, 7 weeks upon arrival and purchased from Jackson Laboratories
(Bar Harbor, ME) were used for the majority of the studies. Male Oprm1-/- mice and
littermate wild-type (WT) controls were generated using heterozygous breeding. Male
Oprk1-/- mice used in this study were generated from mating pairs of Oprk1-/- purchased
from Jackson Laboratories and maintained via homozygous breeding. Male C57BL/6J
mice, originally from Jackson Laboratories but generated within the colony, were used
as their wild type (WT) controls because this was the background strain used in all of the
genetic lines. Mice were housed up to 5 per cage (or in pairs for NIH experiments) in
polycarbonate cages and maintained under a 12 h light-dark cycle (lights on at 0700
hours) in a temperature (22 °C) and humidity-controlled environment. Food and water
were available ad libitum. All experiments were approved by the Institutional Animal
Care and Use Committee at the University of Pennsylvania.
Drugs
Buprenorphine hydrochloride (Sigma, St. Louis, MO and NIDA) and norbinaltorphimine
(nor-BNI; Tocris Bioscience, Ellisville, MO) were administered at doses previously found
to have antidepressant effects in C57BL/6J mice (Falcon et al., 2015). Doses of
morphine sulfate (Spectrum Chemical, New Brunswick, NJ), U50,488 (Sigma),
naltrexone hydrochloride (Sigma), and cyprodime hydrochloride (Tocris) were chosen
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based on results from pilot studies investigating their antinociceptive effects.
Buprenorphine and nor-BNI were dissolved in distilled water and injected
intraperitoneally (i.p.). Morphine and naltrexone were dissolved in physiological saline
and injected i.p. Cyprodime was dissolved in 1% ethanol and delivered by i.p. injection.
Mice in the control groups were injected with vehicle or saline where appropriate. All
doses were calculated according to the base weight of the drug and administered in a
volume of 10 ml/kg.
Hot plate test
Mice were individually placed onto a hot plate heated to 55°C and enclosed by a
Plexiglas container. The latency for the mouse to lick the hindpaw or jump was recorded.
An 80-second cut-off was imposed to avoid tissue damage. The non-selective opioid
antagonist naltrexone (1 mg/kg) (n = 6-7 per group) and selective MOR antagonist
cyprodime (10 mg/kg) (n= 8-16 per group) were injected 1 hour prior to morphine or
U50,488 administration and animals were tested 30 minutes later to determine the MOR
and KOR antagonist properties of each drug. To assess the protracted effects of BPN on
MOR activity, animals were examined for baseline antinociceptive response 24 hours
after BPN (0.25 mg/kg) and then tested 30 minutes after morphine (10 mg/kg)
administration (n = 9 per group). Data for this experiment is expressed as percentage of
baseline (pre-morphine) response.
Novelty-induced hypophagia (NIH) test
Mice were pair housed and trained to eat a palatable food (three peanut butter chips
presented in a small, clear petri dish) in a home feeding cage. Opaque, black, plastic
dividers were placed inside each cage to separate the mice during home cage training
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sessions. Mice were allowed to habituate to the dividers for 1 hr before the start of the
training session. Animals were trained daily in 15-min sessions until they met the criteria
of three consecutive days with approach latencies of 30 seconds or below. For novel
cage testing, mice were placed in an empty, clear polycarbonate cage (25.5 × 46 × 20
cm) with bright lighting (60 W light bulb) and scented with lemon (20% Lemon Joy
solution). There was no food deprivation or habituation period prior to the novel cage
test. The novel cage test session was videotaped, and the latency to approach during
the 15-min test session was measured. The approach latency was defined by the time it
took the mouse to approach the dish in the center of the arena and begin feeding.
In Experiment 1, mice were treated with BPN (0.25 mg/kg) immediately after their
last training session and tested 24 hr later in the novel environment (n = 8-19 per group).
Similarly, in Experiment 2 mice were injected with morphine (10 mg/kg) or nor-BNI (10
mg/kg) and tested 24 hr later (n = 10-22 per group). In Experiment 3 mice were injected
with cyprodime (10 mg/kg) 24 hr or 1 hr before testing (n = 10-25 per group). In
Experiment 4, mice were either pre-treated with naltrexone (1 mg/kg) 1 hr before BPN
(0.25 mg/kg) and tested 24 hr later or treated with naltrexone 24 hr after BPN and tested
1 hr later (n = 9-19 per group).
Data Analysis
One-way and two-way ANOVAs were performed to determine the significance of
differences between experimental groups. Significant overall main effects or interactions
were followed by Holms-Sidak’s post hoc test. Unpaired two- tailed Student’s t tests
were applied where appropriate. For all tests, p < 0.05 was considered statistically
significant. Data are expressed as mean ± SEM.
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Results
	
  
Effects of MOR and KOR disruption on BPN’s behavioral effects in the NIH test
Acquisition of conditioned approach behavior to the palatable food was significantly
diminished in Oprm1-/- mice (Figure 3.1). Repeated measures two-way ANOVA
revealed a significant main effect of genotype [F (2, 71) = 12.89, p < 0.001] and time [F
(13, 923) = 89.57, p < 0.001], in addition to a significant genotype*time interaction [F (26,
923) = 3.724, p < 0.001]. Between the second and tenth day of training Oprm1-/- took
significantly longer to reach stable approach latencies compared to WT and Oprk1-/mice (p < 0.05). A main effect of genotype was also observed in terms of days taken to
reach criteria [F (2, 68) = 6.102, p = 0.004]. Oprm1-/- were slowest to meet the criteria of
three consecutive days with approach latencies under 30 seconds (p < 0.01).
The behavioral effects of BPN (0.25 mg/kg) in the NIH test 24 h postadministration were assessed in Oprm1-/-, Oprk1-/-, and WT mice (Figure 3.2). A
significant genotype*treatment interaction was observed for latency to approach the food
[F (2, 70) = 3.573, p = 0.033] and amount of food consumed [F (2, 69) = 3.882, p =
0.025] in the novel arena. Post-hoc tests revealed BPN significantly reduced approach
latencies and increased food consumption in WT (p < 0.05) and Oprk1-/- (p < 0.001)
mice, but not Oprm1-/- mice.
Effects of nor-BNI and morphine in the NIH test 24 h post-administration
The effects of nor-BNI (10 mg/kg) and morphine (10 mg/kg) treatment on approach
behavior in the NIH test 24 hr post-administration were assessed in WT animals (Figure
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3.3). One-way ANOVA revealed no significant effects of treatment on approach latencies
[F (2, 44) = 0.4651, p = 0.631] or food consumption [F (2, 44) = 1.972, p = 0.151].
Effect of selective MOR antagonist cyprodime in the NIH test 1 hr and 24 hr postadministration
The effects of cyprodime (10 mg/kg) treatment on approach behavior in the NIH test 1 h
and 24 h post-administration was evaluated in WT animals (Figure 3.4). One-way
ANOVA revealed a significant effect of treatment on latency to approach [F (2, 46) =
7.710 P = 0.001 and food consumption F (2, 43) = 5.708 P = 0.006] in the novel arena.
Cyprodime administered 1 hr prior to testing significantly reduced latency to approach
the food reward (p < 0.01) and increased the amount of food consumed (p < 0.05). This
effect was not observed when cyprodime was administered 24 hr prior to testing.
Cyprodime’s selectivity for MOR antagonism was confirmed using the hot plate
test (Figure 3.5). One-way ANOVA revealed a significant effect of treatment on
antinociceptive response [F (4, 46) = 7.513, p < 0.0001]. Antinociception was
significantly increased in animals treated with morphine (10 mg/kg, p < 0.0001) or
U50,488 (10 mg/kg, p < 0.05). Pre-treatment with cyprodime (10 mg/kg) significantly
blocked antinociception induced by both morphine (p < 0.001), but not U50,488.
Pharmacological blockade of opioid receptors does not block BPN’s behavioral effects in
the NIH test.
Next, we determined the effects of pharmacological blockade of opioid receptors on
BPN’s behavioral effects in the NIH test (Figure 3.6). The effects of naltrexone (1 mg/kg)
pre-treatment or post-treatment in combination with BPN (0.25 mg/kg) were measured in
WT mice. Two-way ANOVA revealed a main effect of BPN [F (1, 70) = 11.20 P = 0.0013]
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and naltrexone [F (2, 70) = 9.023 P = 0.0003] on approach latency in the NIH test.
Treatment with naltrexone alone significantly reduced approach latency in the NIH test
BPN’s ability to reduce latency to approach in the novel arena was not affected by either
pre-treatment (1 hr prior to BPN administration, 24 hr prior to test) or post-treatment (24
h after BPN administration, 1 hr prior to testing). Similarly, food consumption in the novel
arena was increased by both BPN [F (1, 71) = 3.615, p = 0.0613] and naltrexone [F (2,
71) = 8.421, p = 0.0005] regardless of time of naltrexone treatment.
The ability of naltrexone to effectively block MOR and KOR agonist activity was
confirmed using the hot plate test (Figure 3.7). One-way ANOVA revealed a significant
effect of treatment on antinociceptive response [F (4, 28) = 8.892, p < 0.001]. The
latency for animals to lick their hindpaw was significantly increased in animals treated
with the selective MOR agonist morphine (10 mg/kg, p < 0.001) or the selective KOR
agonist U50,488 (10 mg/kg, p < 0.01). Pre-treatment with naltrexone (1 mg/kg)
significantly blocked antinociception induced by both morphine (p < 0.001) and U50,488.
Effect of BPN treatment on morphine-induced antinociception 24 hr post-administration
BPN’s activity at the MOR 24 h post-administration was determined using the hot plate
test (Figure 3.8). BPN (0.25 mg/kg) administered 24 h prior to morphine significantly
reduced morphine-induced antinociception compared to vehicle treated animals (t =
2.971, p < 0.01).
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Discussion
We report here for the first time two important findings concerning the pharmacological
properties underlying BPN’s mechanism of antidepressant action and the involvement of
the opioid system in mediating behavioral states etiologically relevant to human
depression. First, utilizing animals with genetic knockdown of individual opioid receptors,
we established that the effects of BPN in the NIH test are dependent on the MOR.
Second, we demonstrate that BPN acts predominantly as a MOR antagonist at the time
of testing (24 h post-administration), and that selective antagonism of the MOR is
sufficient to alleviate the aversive effects of novelty on conditioned approach behavior for
palatable food. Altogether, these data provide supportive preclinical evidence for the
modulation of MOR activity as an integral component of BPN’s therapeutic effects.
The NIH test is a conflict-based paradigm that assesses stress-induced changes
in motivational salience for a palatable food reward. Chronic treatment with selective
serotonin reuptake inhibitors is reported to reduce approach latency for food in a novel
environment in certain strains of rodents (Bodnoff et al., 1988; Bodnoff et al., 1989;
Dulawa and Hen, 2005; Bechtholt et al., 2008). C57BL/6 mice, however, demonstrate a
refractory response to SSRIs in this paradigm (Balu et al., 2009a; Robinson et al., 2016).
Our laboratory has previously shown a single administration of low dose BPN to reduce
novel arena approach latency in C57BL/6 mice when tested 24 hr post-administration
(Falcon et al., 2015). This time point was chosen because BPN treatment induces MOR
dependent hyperactivity in C57BL/6 mice that could obfuscate measures of behavioral
output in the NIH test (Marquez et al., 2007; Falcon et al., 2015). Due to its complex
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pharmacology (Lutfy and Cowan, 2004), the role of individual opioid receptors in
mediating BPN’s behavioral response in the NIH test are not well understood. Thus, the
primary aim of these studies was to systematically dissociate MOR versus KOR
mediated mechanisms of action in the NIH paradigm.
The present study is the first to show that genetic deletion of MOR abolishes the
behavioral effects of BPN in the NIH test. MORs are well known to play an important role
in mediating the reinforcing properties of rewarding stimuli. Oprm1-/- mice fail to show
conditioned place preference for drugs of abuse (Matthes et al., 1996; Kieffer and
Gaveriaux-Ruff, 2002) in addition to reduced operant and hedonic responding for
palatable food rewards (Papaleo et al., 2007). In the current study, Oprm1-/- mice
displayed a marked deficit in acquiring conditioned approach behavior towards the
peanut butter chips during training sessions. Interestingly, these animals did eventually
develop stable approach latencies, suggesting that attribution of incentive salience to
palatable food can occur independently of MOR activity, possibly through adoption of
other feeding-related pathways (Menzies et al., 2013). Oprm1-/- and Oprk1-/- did not
significantly differ from WT in their final baseline approach latency in the novel arena.
Thus, the pure absence of individual receptors does not appear to mitigate the effects of
stress in this paradigm. This is in contrast to previous studies that have reported
increased behavioral resistance to stress in Oprk1-/- mice (Redila and Chavkin, 2008;
Falcon et al., 2016a) and reduced anxiogenic behavior in Oprm1-/- mice (Filliol et al.,
2000). However, the present study is not directly comparable due to the differences in
the behavioral tests measured. Interestingly, BPN efficacy in the NIH test was more
pronounced in Oprk1-/- compared to WT mice. This may be due to compensatory
upregulation of delta opioid receptors (Slowe et al., 1999), which have been shown to
heterodimerize with MOR (Gomes et al., 2000).
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Pre-treatment with the non-selective opioid antagonist naltrexone did not alter
behavioral response to BPN in the NIH test. Similarly, naltrexone administered 24 hr
post BPN (1 hr prior to testing) did not block BPN’s effect on approach behavior in the
novel arena. Naltrexone was administered at a dose experimentally confirmed to
antagonize opioid activity at both the MOR and KOR. Thus, MOR activation by BPN is
not required to obtain subsequent behavioral effects measured at 24 hr postadministration. This was confirmed in a separate experiment showing that administration
of morphine had no effect in the NIH test when assessed 24 hr post-administration.
Interestingly, treatment with the KOR antagonist nor-BNI was also ineffective in reducing
approach latency in the NIH test. Although this data corroborates our findings with
knockout animals, it is contradictory to other studies demonstrating behavioral response
to nor-BNI in the NIH test conducted in mice or rats (Almatroudi et al., 2015; Huang et
al., 2016). This discrepancy may be attributed to differences in procedural execution or
strain differences in behavioral response to KOR antagonists in this paradigm.
One of the more striking findings arising from the present study is that treatment
with the selective MOR antagonist cyprodime was sufficient to reduce approach latency
in the NIH test. Notably, cyprodime’s effects were observed 1 hr post-administration but
not 24 hr post-administration, indicating acute, but not protracted, behavioral effects of
this drug. Studies conducted by Almatroudi et al. (2015) showed no behavioral effect of
the irreversible MOR antagonist CCAM in the NIH test when administrated 48 hr prior to
testing. However, CCAM may more closely model genetic deletion of MORs rather than
the competitive blockade of MOR activity by cyprodime described here. Studies
characterizing the antinociceptive effects of BPN have shown it to exhibit a rapid onset
of action at the MOR followed by slow receptor dissociation, resulting in a prolonged
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blockade of MOR for hours following injection (Cowan et al., 1977; Walker et al., 1995).
In the present study we confirmed that pretreatment of BPN at the dose used in NIH
testing antagonized the antinociceptive effects of morphine when tested 24 h postadministration of BPN. Thus, the eventual blockade of MORs, as opposed to the brief
period of MOR activation, likely mediates the protracted effects of BPN in the NIH test.
Given the role of MOR activation in mediating appetitive control, it is somewhat
counterintuitive that blockade of MORs reinstated motivational behavior for palatable
food. However, MORs are also known to modulate stress-induced changes in dopamine
outflow in key brain regions involved in the processing of reward. Activation of MOR in
the ventral tegmental area (VTA) has been shown to reduce dopamine transmission in
the nucleus accumbens (NAc), a region highly implicated in the presentation of goaldirected behavior (Berridge, 2012a; Latagliata et al., 2014). Moreover, local infusion of a
MOR agonist into the central amygdala reduced open arm time in the elevated plus
maze, suggesting a MOR mediated induction of anxiety-like behavior during exposure to
novelty stress (Wilson and Junor, 2008). Thus, MOR activity may exert context-specific
regulation of circuitries involved in reward processing, so as to promote reward-seeking
behavior under basal conditions but not stressful conditions. Consequently, antagonism
of MORs during exposure to acute stress may prevent stress-induced decreases in
affective behavior.
In conclusion, these studies propose a novel mechanism of action for BPN’s
antidepressant like effects in the novelty-induced hypophagia test, a behavioral measure
of stress-induced motivational conflict. Utilizing genetic and pharmacological tools, we
present a systematic approach to characterizing the role of opioid receptors in mediating
affective behavior. The results of this study encourage further investigation into the
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identification of neurobiological mechanisms underlying the effects of BPN in specific
behavioral domains.
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FIGURE 3.1

Effect of genotype on home cage training. A) Oprm1-/- mice exhibited higher
approach latencies compared to WT mice during training and B) took significantly longer
to reach criteria compared to WT mice. n = 18-36 per group. (* p < 0.05, **p < 0.01, ***
p < 0.001, **** p < 0.00001 compared to WT). Data is depicted as mean ± SEM.
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FIGURE 3. 2

	
  
	
  
BPN’s behavioral effects in the NIH test are blocked in Oprm1-/- mice. A). BPN
reduced latency to approach and B) increased food consumed in WT and Oprk1-/- mice
but not Oprm1-/- mice. n = 8-19 per group. (*p < 0.05, ***p < 0.001 compared to vehicle).
Data are depicted as mean ±SEM.
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FIGURE 3.3

Treatment with morphine or nor-BNI does not affect behavior in the NIH test 24 h
post administration. Treatment with a MOR agonist or KOR antagonist had no effect
on A) approach latency in the NIH test or B) amount of food consumed in the novel
arena. n = 10-22 Data are depicted as mean ±SEM.
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FIGURE 3.4

Treatment with cyprodime reduced approach latency in the NIH test 1 h post
administration. Treatment with a MOR antagonist was sufficient to A) reduce approach
latency and B) increase food consumption 1 h post administration but not 24 h post
administration. n = 10-25. (**p < 0.01 compared to vehicle). Data are depicted as mean
±SEM.
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FIGURE 3.5

Cyprodime selectively blocks morphine-induced antinociception. Pretreatment with
cyprodime blocked morphine induced antinociception but not U50,488. n= 8 -16 per
group. (*p < 0.05, ****p < 0.0001 compared to saline + vehicle, &p < 0.05 compared to
saline + morphine). Data are depicted as mean ±SEM.
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FIGURE 3.6

Pharmacological blockade of opioid receptors does not block BPN’s behavioral
effects in the NIH test. A) Combination treatment of BPN and naltrexone reduced
approach latency in the novel arena. Naltrexone given alone also reduced approach
latency in the NIH test. B) Naltrexone treatment increased food consumption in the novel
arena. n = 9-19. (**p < 0.01 compared to vehicle, ###p < 0.001 compared to saline).
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FIGURE 3.7

Naltrexone blocks morphine and U50,488-induced antinociception. Naltrexone
pretreatment blocked antinociceptive effects of morphine and U50,488. n = 6-7 per
group. (**p < 0.01, ***p < 0.001 compared to saline + saline, &&&p < 0.001 compared to
saline + morphine, #p < 0.05 compared to saline + U50). Data are depicted as mean
±SEM.
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FIGURE 3.8

Pretreatment with BPN blocks morphine-induced antinociception. (**p < 0.01
compared to vehicle). n = 9 per group. Data are depicted as mean ±SEM.
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Abstract
	
  
Both genetic background and pre-existing stress play critical roles in the effects of
antidepressant drugs. The current studies showed this principal by demonstrating that
exposure to the stress hormone corticosterone (CORT) allowed behavioral and
neurogenic effects to emerge following chronic treatment with fluoxetine of C57BL/6
mice, a strain ordinarily resistant to these effects. Adult male mice were implanted
subcutaneously with 21-day slow-release CORT pellets (10 mg) or placebo and then cotreated with 5 mg/kg fluoxetine (b.i.d., i.p.) or saline for 14 days. Animals were then
assessed for approach behavior in the novelty-induced hypophagia (NIH) test,
hippocampal cell proliferation, corticosteroid receptor expression, and CORT plasma
levels. Co-treatment of CORT with fluoxetine significantly reduced approach behavior in
the novel environment of the NIH test and increased hippocampal cell proliferation
whereas fluoxetine given alone was ineffective. CORT given alone did not alter
approach behavior in the novel environment and caused a smaller increase of cell
proliferation. The CORT effect was blocked by adrenalectomy and was likely due to
increased adrenal feedback. Cell proliferation in CORT-treated animals was associated
with reduced mineralocorticoid, but not glucocorticoid, receptor mRNA expression.
Although the pellets were advertised to release CORT for 21 days, plasma CORT levels
were increased at 1 day after implantation but were not sustained when measured at 7
days or longer intervals. Nevertheless, the transient CORT increase was sufficient to
induce long-lasting behavioral and molecular changes when followed by fluoxetine
treatment. These studies warrant further investigation into the role of glucocorticoids and
environmental stress as adjunctive facilitators of the response to antidepressants,
especially for treatment-resistant patients.
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Introduction
Major Depressive Disorder (MDD) is one of the most common psychiatric disorders, with
a lifetime prevalence of 17% in the United States and 4% worldwide (Kessler et al.,
2005; Eaton et al., 2008). In terms of years lost to disability, MDD is considered one of
the most disabling medical conditions and is predicted to be a leading contributor to the
worldwide burden of disease by 2030 (Mathers and Loncar, 2006). The majority of
pharmacotherapies developed for the treatment of MDD target brain monoamine
systems, primarily serotonin (5-HT), norepinephrine, and dopamine. The most common
of these, the selective serotonin reuptake inhibitors (SSRIs) and selective
norepinephrine reuptake inhibitors (SNRIs), comprise a large proportion of
pharmaceutical sales and are considered first line treatment for MDD. Unfortunately, an
estimated 40% of patients fail to respond to these therapies (Cipriani et al., 2009;
Culpepper, 2010). Further insight into the neurobiological mechanisms underlying
antidepressant response is needed for the development of more efficacious
antidepressant regimens.
The combination of genetic vulnerabilities and environmental factors, such as
stress, are thought to be significant contributors to the onset of depression in humans
(Charney and Manji, 2004). The likelihood of experiencing a depressive episode is
greatly increased following a stressful life event or after accumulation of chronic minor
stresses (Caspi et al., 2003; Harkness and Monroe, 2006). Moreover, many patients
suffering from depression exhibit signs of dysfunctional hypothalamic-pituitary-adrenal
(HPA) axis activity, as demonstrated by elevated basal cortisol levels and resistance to
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dexamethasone, an exogenous steroid that suppresses cortisol in healthy individuals
(Pariante and Miller, 2001b; Gillespie and Nemeroff, 2005). Interestingly, successful
antidepressant treatment is often associated with restored suppression of HPA axis
response (Schule, 2007). Together, these findings suggest a potential role of stress
hormones, such as cortisol (corticosterone (CORT) in rodents), in the pathology and
treatment of depression.
CORT produces its effects in the central nervous system via activation of
glucocorticoid (GR) and mineralocorticoid (MR) receptors. Though these receptors are
ubiquitous throughout the brain, they are highly abundant in the hippocampus, where
they provide crucial inhibitory feedback signals to the HPA axis (Sapolsky et al., 1984;
Jacobson and Sapolsky, 1991). A reduction or absence of these inhibitory signals can
promote hyperactivation of the axis and augmented secretion of glucocorticoids
(Anacker et al., 2011; McEwen et al., 2012). In a healthy individual, elevated
corticosteroid activity helps facilitate the physiological and behavioral adaptations
required to appropriately respond to stressors and reinstate homeostasis. However,
prolonged exposure to CORT can inhibit the proliferation and survival of adult-born
hippocampal neurons, which have been shown to play an important role in the
behavioral and neuroendocrine components of stress responses in rodents (Gould and
Tanapat, 1999; Snyder et al., 2011). Conversely, chronic treatment of normal rodents
with SSRIs, such as fluoxetine, increases hippocampal neurogenesis and neurotrophins
such as brain derived neurotrophic factor (BDNF) (Duman and Monteggia, 2006;
Schmidt and Duman, 2006; Krishnan and Nestler, 2008). Increased hippocampal
neurogenesis is associated with behavioral indications of antidepressant efficacy in
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rodents, such as reduced hyponeophagia and increased performance in the forced swim
test (Dranovsky and Hen, 2006).
Our laboratory has previously shown that not all strains of mice respond to
antidepressant treatments. Normal C57BL/6 mice are insensitive to the effects of chronic
fluoxetine treatment, measured in the novelty-induced hypophagia (NIH) test, a conflictbased test in which motivation to approach a highly palatable food is suppressed by a
novel environment. Nor did C57BL/6 mice exhibit increase hippocampal cell proliferation
in response to the antidepressant treatment (Balu et al., 2009a). In a small clinical study,
Dinan et al. (1997) found that 4-day dexamethasone therapy significantly enhanced
antidepressant response to SSRIs in treatment-resistant patients. Therefore, we
hypothesized that activation of stress circuitry might be important to reveal the
behavioral and neurogenic effects of fluoxetine in this non-responsive mouse strain.
CORT is a vital component of the central nervous system’s stress response
circuitry. Although corticosteroids alone do not encompass all aspects of stress
exposure (Belzung, 2014), previous studies have shown that chronic CORT exposure
can induce a depressive-like motivational state in rodents that is similar to that produced
by a chronic mild stress paradigm (Gourley et al., 2008). Moreover, CORT treatment
alone is sufficient to alter molecular targets that are implicated in depression and
antidepressant efficacy, such as hippocampal neurogenesis (Bilsland et al., 2006;
Gourley and Taylor, 2009). In the current study we investigated the effects of exposure
to commercial CORT pellets for 21 days in augmenting fluoxetine’s behavioral and
proliferative effects in C57BL/6 mice. The results of this study showed that fluoxetine
produced behavioral effects in the NIH test only in mice exposed to CORT. Furthermore,
CORT administration with fluoxetine co-treatment augmented hippocampal cell
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proliferation, an effect potentially mediated by alterations in hippocampal corticosteroid
receptor expression. Interestingly, analysis of plasma at the end of treatment revealed a
paradoxical decrease in CORT levels in animals treated with the pellets, suggesting that
the CORT pellets did not work as advertised. Adrenalectomized animals implanted with
CORT pellets revealed a sharp drop in CORT plasma levels by day 7 of treatment,
indicating that this method of CORT exposure produced transiently elevated, but not
sustained, CORT levels. Nevertheless, these experiments revealed the important finding
that CORT exposure potentiates the behavioral and neurogenic effects of chronic
fluoxetine administration in a mouse strain that is otherwise non-responsive to this
antidepressant treatment.
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Materials and Methods
Animals
Intact and adrenalectomized male C57BL/6J, 7-8 weeks old upon arrival, were
purchased from Jackson Laboratories (Bar Harbor, ME). Mice were housed in groups of
4 (except for those used in the NIH test whom were housed in in pairs) in polycarbonate
cages and maintained on a 12 hour light-dark cycle (lights on at 0700 hours) in a
temperature (22 °C)- and humidity-controlled environment. Food and water were
available ad libitum. All experiments were approved by the Institutional Animal Care and
Use Committee at the University of Pennsylvania.
Experimental Design
Experiment 1: Intact animals were implanted with CORT pellets (10 mg) or placebo
pellets. Beginning on day 7 of CORT treatment, animals were dosed with either
fluoxetine (5 mg/kg b.i.d., i.p.) or saline daily for the remaining 14 days of the
experiment. Cohort 1: Animals were tested in the NIH and home cage test on the last
two days of drug treatment (n =8-10 per group). Cohort 2: Animals received a single
injection of BrdU on the last day of drug treatment and were sacrificed 24 hours later. In
these animals hippocampal tissue was dissected and analyzed for BrdU positive cells
and corticosteroid mRNA expression. Trunk blood was collected at time of sacrifice and
analyzed for plasma CORT levels (n = 15-19 per group).
Experiment 2: Adrenalectomized animals were implanted with CORT pellets (10 mg) or
placebo pellets and received chronic fluoxetine treatment as described in Experiment 1.
All mice received additional CORT replacement through the drinking water (25 µg/ml in
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0.9% saline) to prevent the loss of electrolyte homeostasis (Funder, 2006) and eliminate
the confounding effects of adrenalectomy alone on neurogenesis (Cameron and Gould,
1994). Animals received a single injection of BrdU on the last day of drug treatment and
were sacrificed 24 hours later. Hippocampal tissue was dissected and analyzed for BrdU
positive cells (n =7-10 per group).
Experiment 3: Intact animals were implanted with CORT pellets (2.5 mg) or placebo
pellets and received chronic fluoxetine treatment as described in Experiment 1. Animals
received a single injection of BrdU on the last day of drug treatment and were sacrificed
24 hours later. Hippocampal tissue was dissected and analyzed for BrdU positive cells
(n = 9-10 per group).
Experiment 4: Adrenalectomized animals were implanted with CORT pellets (10 mg) or
placebo pellets and then sacrificed 1, 7, 14, or 21 days after implantation. Trunk blood
was collected at time of sacrifice and analyzed for plasma CORT levels (n = 5-6 per
group).
Drug Formulation
CORT pellets (2.5 mg and 10 mg, 21 day release, Innovative Research of America,
Sarasota, FL, USA) were composed of a proprietary matrix of cholesterol, cellulose,
lactose, phosphates and stearates designed to facilitate continuous and sustained
diffusion of CORT over a period of 21 days. Placebo pellets consisted of the same
matrix without the active product. Fluoxetine hydrochloride (5 mg/kg; Anawa, Zurich)
was dissolved in distilled water and delivered by intraperitoneal (i.p.) injection in a
volume of 10 ml/kg. Fluoxetine was administered twice daily because, due to its half-life,
this dosing strategy results in relatively stable plasma levels (Hodes et al., 2010) and
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occupation of brain serotonin transporters (Hirano et al., 2004). Control animals received
saline (0.9% NaCl). 5-Bromo-deoxyuridine (BrdU; Roche Applied Sciences Indianapolis,
IN) was dissolved in warm saline at a dose of 200 mg/kg and administered i.p. in a
volume of 10 ml/kg.
Novelty Induced Hypophagia (NIH) Test
Mice were pair housed and trained to eat a palatable food (three peanut butter chips
presented in a small, clear petri dish) in a home cage environment. Animals were trained
daily in 15-minunte sessions until they met the criteria of three consecutive days with
approach latencies of 30 seconds or less. Opaque, black, plastic dividers were placed
inside each cage to separate the mice during training of home cage training sessions.
Mice were allowed to habituate to the dividers for 1 hour before the start of the training
session. Once all animals had met criteria, training sessions were suspended and drug
treatments were initiated. Three days before novel testing all animals were re-exposed
to the peanut butter chips through additional training sessions. For novel cage testing,
peanut butter chips were presented in the center of an empty, clear polycarbonate cage
(25.5 × 46 × 20 cm) with bright lighting (60 W light bulb) and scented with lemon (20%
Lemon Joy solution). Novel cage testing was videotaped. Mice were placed into the test
cage and the latency to approach during the 15-minute test session was measured. The
approach latency was defined as the time to ingestion. There was no food deprivation or
habituation period prior to the novel cage test. All behavioral testing took place during
the light phase. The home cage test was performed the day after the novel cage test.
BrdU Incorporation Using Flow Cytometry
Flow cytometry is a frequently used method for analyzing newly dividing cells in the
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hippocampus. This method has been previously validated by our lab and others, and
compared to results obtained from immunostaining (Bilsland et al., 2006; Balu et al.,
2009b; Spoelgen et al., 2011). BrdU labeling was measured in cells displaying the
nuclear marker 7-aminoactinomycin D (7-AAD) by flow cytometry as previously
described (Balu et al., 2009b). Briefly, mice were decapitated 24 hours following BrdU
injection, their brains quickly removed, and the hippocampus dissected. Hippocampal
tissue was manually minced, digested using an enzymatic mixture (1 mg/ml papain,
Roche Applied Science; 0.1 M L-cysteine, Sigma-Aldrich, St. Louis, MO), and then
mechanically triturated to form a single cell suspension. Cells were fixed, permeabilized,
and stained using the flourescein isothiocyanate (FITC) BrdU Flow Kit (BD Biosciences,
San Jose, CA). Data were collected on the same day using a BD FACS Canto System
(BD Biosciences) at the University of Pennsylvania Flow Cytometry Core Facility.
Background signals were controlled for by collecting data from a BrdU-free control. All
data were analyzed using BD FACSDiva Software (BD Biosciences).
Analysis of corticosteroid receptor expression using quantitative real-time polymerase
chain reaction (qRT-PCR)
RNA was extracted with Trizol reagent (Gibco BRL, Life Technologies, NY) and purified
using the RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufactures’
instructions. RNA concentrations were measured and 300 ng/µl RNA was used as a
template to synthesize c-DNA using the Superscript Vilo c-DNA Synthesis kit (Invitrogen,
Carlsbad, CA, USA). All reactions were performed with a master mix of SYBR green
(Applied Biosystems, Austin, TX) and 300 nM primers (final concentration). Quantitative
real-time polymerase chain reactions (qRT-PCR) were run using the Stratagene
MX3000 and MXPro QPCR software. Cycling parameters were as follows: 95°C for 10
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min, 40 cycles at 95°C (30 s) and 60°C (1 min), ending with a melting curve analysis to
control for amplification. All reactions were performed in triplicate and the mean cycle
threshold was used for analysis. The mRNA levels of target genes were normalized to
the house- keeping gene TATA binding protein (TBP) using the 2Δct method. Primer
sequences are available upon request.
Analysis of plasma CORT using enzyme-linked immunosorbent assay (ELISA)
Trunk blood was collected at time of sacrifice, which occurred between 8-10 am for all
experiments. Blood was stored in 0.5 mL heparin and centrifuged at 3000 rpm for 20
minutes. Plasma was removed and stored frozen (–80º C) until analysis. The amount of
CORT in the plasma from each sample was measured in duplicate by ELISA following
the manufactures instructions (Immunodiagnostic Systems, Fountain Hills, AZ). Intraassay variability for the CORT kit ranged from 5.9%-7.0%, inter-assay variability ranged
from 8.2-8.9%; mean assay sensitivity was 0.17 ng/ml.
Data Analysis
One-way and two-way ANOVA were performed to examine the significance of
differences between treatments. Significant overall main effects (p < 0.05) or interactions
showing a trend (p < 0.10) were followed by Tukey or Bonferroni post-hoc tests. For all
follow-up tests, p < 0.05 was considered statistically significant. Data are expressed as
mean ± SEM.
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Results
The effects of 10 mg CORT pellet exposure and fluoxetine treatment on behavior

Mice were randomly assigned to either placebo or CORT pellet exposure, and then
further separated into either saline or fluoxetine treatment groups. As seen in Figure
4.1A, a two-way repeated measures ANOVA revealed a significant interaction [F(9,102)
= 3.761, p < 0.001] and main effect [F(3,102) = 12.68, p < 0.001] of time on body weight
during drug treatment. Placebo-treated animals exhibited significant weight gain by day
14 (p < 0.05). Although CORT-exposed animals failed to gain weight within the initial 7
days of treatment, animals subsequently treated with fluoxetine showed significant
weight gain by day 21 (p < 0.001) whereas saline treated animals continued to show
inhibited weight gain. The overall change in body weight (from day 1 to day 21) shown in
Figure 4.1B illustrates a significant main effect of treatment with fluoxetine [F(1, 34) =
8.830, p < 0.01].
The behavioral effects of CORT and fluoxetine treatment were then measured in
the NIH test. Exposure to a novel environment increased approach latency [F(1,65) =
972.4, p < 0.0001] and reduced the amount of food consumed [F(1,68) = 136.0, p <
0.0001] compared to home cage in all treatment groups. There was a significant
interaction between CORT exposure and fluoxetine treatment in approach latencies in
the novel environment [F(1,33) = 8.041, p < 0.01]. CORT-exposed animals treated with
fluoxetine displayed significantly lower approach latencies compared to CORT-exposed
animals treated with saline. Moreover, fluoxetine treatment had no effect on approach
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latency in placebo-treated animals in the novel environment (Figure 4.2A). There were
no significant differences in food consumption in the novel environment between drug
treatment groups (Figure 4.2B). In the home cage, CORT treatment significantly reduced
latency to approach [F(1, 33) = 4.772, p < 0.05] and increased the amount of food
consumed compared to placebo treated animals [F(1, 34) = 4.956, p < 0.05] (Figure
4.2C and 4.2D).

The effects of 10 mg CORT pellet exposure and fluoxetine treatment on hippocampal
cell proliferation, CORT plasma levels and corticosteroid receptor expression
In a separate cohort, animals received a single injection of BrdU on the last day of drug
treatment and were sacrificed 24 hours later. Hippocampal tissue was analyzed for BrdU
positive cells and corticosteroid mRNA expression. Additionally, trunk blood was
collected at time of sacrifice and analyzed for plasma CORT levels. As seen in Figure
4.3A, flow cytometric analysis of hippocampal tissue revealed that in placebo treated
animals, fluoxetine had no effect on hippocampal cell proliferation. Interestingly, CORTexposure significantly increased hippocampal cell proliferation compared to placebo
treated animals [F(1,59) = 50.87, p < 0.001]. Moreover, there was a significant
interaction between CORT exposure and fluoxetine treatment on neurogenesis [F(1, 59)
= 6.702, p < 0.05]. Post hoc multiple comparisons revealed that CORT-exposed animals
treated with fluoxetine displayed significantly higher hippocampal cell proliferation
compared to CORT-exposed animals treated with saline.
Analysis of circulating CORT levels at the time of sacrifice revealed that
exposure to CORT pellets significantly reduced CORT plasma levels in both saline and
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fluoxetine treated animals by approximately 50% when measured on day 21 [F(1, 66) =
36.06, p < 0.001] (Figure 4.3B). Fluoxetine treatment did not alter CORT levels.
Glucocorticoid (GR) and mineralocorticoid (MR) receptor transcription was
examined in the hippocampus as a potential molecular mechanism underlying the
CORT-induced neurogenic response to fluoxetine in C57BL/6 mice. There was no
significant effect of CORT or fluoxetine on GR mRNA expression (Figure 4.3C).
However, exposure to CORT significantly reduced hippocampal MR mRNA expression
in both saline and fluoxetine treated animals [F(1,68) = 4.276, p < 0.05] (Figure 4.3D).
The effects of adrenalectomy on 10 mg CORT pellet exposure induced hippocampal cell
proliferation
To investigate the mechanisms underlying the increase in hippocampal cell
proliferation by CORT pellets, adrenalectomized animals were used to examine the
effects of 10 mg CORT pellet exposure and fluoxetine treatment on hippocampal
neurogenesis in the absence of adrenal feedback. There was a significant main effect of
CORT on cell proliferation [F(1, 30) = 5.298, p < 0.05] and a trend towards an interaction
[F (1, 30) = 3.372 p = 0.08]. As illustrated in Figure 4.4A, adrenalectomized CORTexposed animals treated with fluoxetine, but not saline, displayed a significant two-fold
increase in cell proliferation compared to placebo treated animals (p < 0.05). However,
CORT treatment did not increase cell proliferation in adrenalectomized animals.
The effects of 2.5 mg CORT pellet exposure and fluoxetine treatment on hippocampal
cell proliferation
We next examined whether a lower dose of CORT pellet exposure combined with
fluoxetine treatment would induce an increase in hippocampal neurogenesis in intact
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animals. There was a significant main effect of CORT pellet exposure [F(1, 35) = 6.477,
p < 0.05] and a significant interaction between CORT pellet exposure and fluoxetine
treatment [F(1, 35) = 4.705, p < 0.05] on hippocampal cell proliferation. As shown in
Figure 4.4B, CORT-exposed animals treated with saline exhibited a significant increase
in cell proliferation compared to placebo treated animals, as in prior studies. In contrast,
the lower dose of CORT pellet was incapable of increasing hippocampal cell
proliferation.
Evaluation of the sustained effects of 10 mg CORT pellet treatment on plasma CORT
levels
To determine whether 10 mg CORT pellets maintain elevated plasma CORT levels for
the advertised duration, adrenalectomized animals were implanted with 10 mg CORT
pellets on day 0 and, CORT plasma levels were assessed on day 1, 7, 14, and 21 postimplantation. As shown in Figure 4.5, plasma CORT levels changed dramatically over
time (F(3,19) = 16.18, p < 0.01), and were no longer in the supraphysiological range by
the seventh day of CORT pellet exposure.
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Discussion
Activation of stress circuitry from implanted CORT pellets produced behavioral and
neurogenic effects from chronic fluoxetine treatment in a strain of mice that would
otherwise have been unresponsive to the effects of the antidepressant. Specifically, cotreatment of CORT with fluoxetine significantly reduced the effects of novelty stress
measured on approach behavior in the NIH test and increased hippocampal cell
proliferation. These two effects of antidepressant treatment have been linked together
because the behavioral response to fluoxetine is blocked in mice that cannot increase
hippocampal cell proliferation (Sahay and Hen, 2007). Although treatment with CORT
alone unexpectedly increased cell proliferation to a lesser extent, this effect was absent
in adrenalectomized mice while the augmented combination treatment effect was
preserved. Measurement of plasma CORT levels revealed that the CORT pellet did not
maintain elevated levels for more than a few days, even though it was expected to be
active for 21 days, suggesting that the impact of the CORT treatment was likely the
after-effect resulting from the supraphysiological levels of acute exposure. Overall, these
findings reveal potential neurobiological mechanisms underlying effective antidepressant
response in a unique model of treatment resistance.
Hyponeophagia, the unconditioned suppression of feeding in a novel
environment, is a behavioral measure of stress that may be sensitive to the anxiolytic
effects of chronic, but not acute, antidepressant treatment with SSRIs (Bodnoff et al.,
1988; Bodnoff et al., 1989; Dulawa et al., 2004; Dulawa and Hen, 2005; Bechtholt et al.,
2007). Fluoxetine’s effect of reducing approach latency to food in a novel environment is
abolished after focal irradiation of the hippocampus or genetic deletion of hippocampal
precursor cells, indicating that hippocampal neurogenesis is a necessary component of
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this behavioral antidepressant response (Santarelli et al., 2003; Surget et al., 2008;
Wang et al., 2008; David et al., 2009). Intriguingly, unlike other mouse strains, C57BL/6
mice did not exhibit reduced hyponeophagia or increased hippocampal neurogenesis
following chronic fluoxetine treatment (Balu et al., 2009a). However, in the present study,
we showed that CORT-exposure via pellet implantation induced a behavioral response
to fluoxetine in the NIH test in this unresponsive strain. Moreover, CORT-exposure in
combination with fluoxetine treatment produced a robust increase in hippocampal
neurogenesis that was not seen in placebo treated animals. Although correlative, the
increased behavioral response to chronic fluoxetine treatment in CORT-treated mice
could be attributed to heightened hippocampal cell proliferation.
Stress is a well-established robust inhibitor of adult neurogenesis (Gould and
Tanapat, 1999; McEwen et al., 2012). Similarly, CORT exposure alone has been shown
to be a negative regulator of hippocampal neurogenesis (Cameron and Gould, 1994;
Wong and Herbert, 2004; Bilsland et al., 2006; Murray et al., 2008; Brummelte and
Galea, 2010). Reduced hippocampal cell proliferation typically coincides with increased
plasma CORT levels, signifying that circulating CORT levels at the time of testing
underlie CORT-induced changes in proliferation (Wong and Herbert, 2006).
Paradoxically, we observed dramatically reduced plasma CORT levels in all CORTexposed animals following the 21-day pellet treatment, while hippocampal cell
proliferation was increased. We suspected this might have been due to unanticipated
changes in adrenal function. The adrenals operate through an inhibitory feedback
system in which increased circulating CORT levels serve as a signal for reduced
synthesis and secretion from the adrenals (Sapolsky et al., 1984; Herman and Cullinan,
1997). CORT pellet treatment may have increased internal negative feedback to the
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point of adrenal inactivation, resulting in reduced endogenous circulating CORT levels
and disinhibition of cell proliferation. To test for this we examined the effects of CORT
pellet and chronic fluoxetine co-treatment on hippocampal cell proliferation in
adrenalectomized animals. Notably, in the absence of adrenal feedback, CORTexposed animals treated with saline did not demonstrate increased neurogenesis
whereas those given fluoxetine still exhibited a proliferative response. Therefore, the
mechanisms underlying the augmented neurogenic effect seen in combination treated
animals cannot be attributed to artifacts of adrenal feedback. It is important to note,
however, that adrenalectomized animals in all treatment groups were supplemented with
a low dose CORT-treatment (25µg/ml) delivered via drinking water. This mode of
delivery produces small rhythmic changes in plasma CORT levels, which have been
shown to be necessary for fluoxetine-stimulated neurogenesis in rats (Huang and
Herbert, 2006). It is possible, then, that rhythmic fluctuations in CORT levels modulate
sensitivity to the proliferative effects of fluoxetine. In spite of this, adrenalectomized
placebo animals treated with fluoxetine did not exhibit increased proliferation,
demonstrating that supplemental CORT alone was not sufficient to induce a neurogenic
response to fluoxetine.
To determine whether a lower dose of CORT could elicit a neurogenic response
in the presence of fluoxetine without increasing proliferation on its own, we evaluated
hippocampal cell proliferation in intact animals treated with 2.5 mg CORT pellets. Similar
to the 10 mg CORT pellet treatment, exposure to 2.5 mg CORT pellet treatment
produced elevated cell proliferation. However, there was no additional effect in the
presence of fluoxetine, suggesting that this dose is sufficient to produce CORT-induced
increases in neurogenesis, but not sufficient to elicit an augmented proliferative
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response when combined with fluoxetine. This finding is in contrast to David et al. (2009)
who showed a low dose of 5 mg/kg/day CORT treatment to be effective in reducing
hippocampal cell proliferation alone and stimulating proliferation when paired with
fluoxetine treatment in C57BL/6 mice. However, whereas the current study utilized a
three-week CORT pellet treatment, David and colleagues had CORT delivered though
drinking water and animals were treated for a substantially longer period of time (7
weeks). Therefore, rhythmic low dose CORT treatment over a longer period of time may
be sufficient to increase neuronal sensitization to fluoxetine in this strain.
Hippocampal MRs and GRs play a vital role in mediating stress responsiveness.
Altered corticosteroid activity can dysregulate the stress response system and enhance
the risk of development of stress-related disorders (Groeneweg et al., 2012). On the
other hand, synergistic interactions between hippocampal corticosteroid receptors and
serotonergic signaling pathways may mediate the effects of CORT exposure on
enhancing the neurogenic responses to fluoxetine in C57BL/6 mice. For example, CORT
treatment has been shown to facilitate fluoxetine-induced enhancement of dopaminergic
modulation at the mossy fiber synapse (Kobayashi et al., 2013).
Consistent with recent findings, CORT treatment reduced hippocampal MR
expression while having no effect on GR expression (Saenz del Burgo et al., 2013),
suggesting that MR expression is more sensitive to the effects of CORT exposure. This
may be due to the fact that MRs exhibit 10-fold higher affinity for CORT compared to
GRs (Joels et al., 2008). Hippocampal MRs selectively contribute to neuronal stability
and excitatory tone and have been shown to mediate behavioral reactivity to a novel
environment (Oitzl et al., 1994; Berger et al., 2006), hence changes in MR expression
and function are likely to impact both hippocampal plasticity and associated behaviors.
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Interestingly, in the current study, MR expression was similar between CORT-exposed
animals treated to either saline or fluoxetine treated, indicating that variations in
expression alone cannot explain the augmented behavioral and neurogenic responses
seen in CORT-exposed animals treated with fluoxetine. However, it is important to note
that MR and GR expression exhibit a diurnal regulation that is modulated by circulating
CORT levels (Herman et al., 1993; Holmes et al., 1995). Since exogenous CORT
treatment has been reported to flatten the natural circadian rhythm of plasma CORT
(Leitch et al., 2003), CORT pellet exposure could potentially alter rhythmic MR and GR
occupancy throughout the day. Thus, the observed neurogenic effects of CORT and
fluoxetine treatment might be mediated by changes in circadian expression of MR and
GRs. Further studies are needed to confirm this.
A major caveat of this study is the lack of sustained CORT release from the pellet
treatment. CORT pellets have been used to model chronically elevated CORT levels, a
physiological indicator of dysregulated HPA axis functioning and risk factor for the onset
of MDD (Goodyer et al., 2010; Owens et al., 2014). On the contrary, we found that
CORT plasma levels dropped precipitously between day 1 and day 7 of CORT pellet
treatment. Rather than a sustained release, the CORT pellets produced a rapid, but
short-lived, elevation of CORT during the initial days of exposure and then became
inactive, resulting in CORT levels falling to the normal physiological range at the time of
the experimental studies. Similar findings were reported in another study evaluating the
performance of pellets designed to release CORT for 7 days in birds. Muller et al. (2009)
found that CORT plasma levels peaked 1-2 days after pellet implantation and reached
placebo levels by day 3. The authors posited that the pellets, being originally designed
for rodents, are not as effectively metabolized in other species. However, our data
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corroborate the findings that the CORT pellets do not reliably produce sustained CORT
release for the indicated length of treatment. In light of this, slow-release CORT pellets
are not appropriate for modeling prolonged elevated CORT levels. Instead, these pellets
may more closely model the effects of exposure to a strong acute stressor, as with posttraumatic stress disorder. Interestingly, the initial surge in CORT levels during the first
few days of treatment was sufficient to induce long lasting molecular and behavioral
changes in treated animals, suggesting that alterations in CORT levels, not necessarily
at a pathological level, can impact the efficacy of fluoxetine.
In conclusion, this study found that exposure to exogenous CORT increases
behavioral and neurogenic sensitivity to chronic fluoxetine treatment in C57BL/6 mice, a
typically non-responsive strain of mice. These data recapitulate the general findings that
genetic background and environment play a fundamental role in antidepressant
response. Although slow-release CORT pellets did not model the effects of sustained
elevated CORT exposure as anticipated, these studies effectively indicate that CORT
exposure is sufficient to reveal the anxiolytic and neuroplastic effects of chronic
fluoxetine treatment in a typically unresponsive strain and could model an augmentation
strategy for treatment-resistant patients. These findings implicate corticosteroid receptor
activity and modulation as a potential variable in the stratification of antidepressant
response in patients with MDD and possibly as a mediator of the effects of
environmental stress on the effects of antidepressants.
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FIGURE 4. 1

Effects of 10 mg CORT pellet and fluoxetine treatment on weight gain. SAL =
Saline, FLX = Fluoxetine, CORT = Corticosterone. Arrow denotes start of fluoxetine
treatment. A) Weight change over time in each treatment group. Placebo treated
animals gained weight over time. CORT/SAL animals displayed inhibited weight gain
whereas CORT/FLX animals showed normal weight gain after beginning FLX treatment.
Symbols represent significant differences compared to day 1: a (PLACEBO/FLX, p <
0.05) b (PLACEBO/SAL, p <0.01) c (CORT/FLX, p < 0.01) (B) Overall weight change
(from day 1 to day 21) showed that fluoxetine treatment increased weight gain in both
placebo and CORT treated animals (n = 9-10 per group). Data is depicted as mean ±
SEM. ##p < 0.01 within placebo or CORT treated groups.
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FIGURE 4. 2

Effects of 10 mg CORT pellet and fluoxetine treatment in the novelty induced
hypophagia test. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A)
Fluoxetine significantly reduced approach latency in the novel arena in animals exposed
to CORT, but not placebo. B) There was no effect of treatment on amount consumed. C)
In the home cage, CORT exposure significantly reduced latency to approach and D)
increased the amount of food consumed (n = 8-10 per group). Data is depicted as mean
± SEM. #p < 0.05 within CORT treated groups, *p < 0.05 between placebo and CORT
treated groups.
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FIGURE 4.3

Effects of 10 mg CORT pellet and fluoxetine treatment on hippocampal cell
proliferation, CORT plasma levels, and hippocampal corticosteroid receptor
expression. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A) Values are
expressed as the number of BrdU-positive cells per 10,000 7-AAD events. Intact animals
exhibited a significant increase in hippocampal cell proliferation after treatment with
CORT. This effect was further augmented in CORT-exposed animals treated with
fluoxetine. Fluoxetine had no effect in placebo treated animals (n = 14-18 per group). B)
CORT treatment significantly reduced plasma CORT levels. Fluoxetine had no additive
effect on CORT levels (n = 15-19 per group). C) CORT had no effect on hippocampal
GR mRNA expression but (D) reduced hippocampal MR mRNA expression (n = 15-19
per group). Data is depicted as mean ± SEM. ###p < 0.001 within CORT treated groups,
***p < 0.001, *p < 0.05 between placebo and CORT treated groups.
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FIGURE 4. 4

Effects of adrenalectomy or low dose CORT exposure on hippocampal cell
proliferation. SAL = Saline, FLX = Fluoxetine, CORT = Corticosterone. A) Values are
expressed as the number of BrdU-positive cells per 10,000 7-AAD events. In
adrenalectomized animals exposed to 10 mg CORT pellets, fluoxetine produced an
increase in proliferation. (n = 7-9 per group. B). In intact animals exposed to 2.5 mg
CORT pellets, hippocampal cell proliferation was increased, but not further augmented
by fluoxetine (n = 9-10 per group). Data is depicted as mean ± SEM. #p < 0.05 within
CORT treated groups, *p < 0.05 between placebo and CORT treated groups.
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FIGURE 4.5

Effects of CORT pellet on plasma CORT levels over time. Adrenalectomized animals
implanted with 10 mg CORT pellets displayed significantly reduced CORT plasma levels
after 7 days of treatment. (n = 5-6 per group). Data is depicted as mean ± SEM.
Absolute mean values are: 247.2 ± 43.92, 20.8 ± 7.02, 34.7 ± 24.44 and 37.6 ± 16.32
ng/ml. ****p < 0.0001, ***p < 0.001 compared to day 1.
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CHAPTER 5: GENERAL DISCUSSION

135	
  
	
  

Summary of findings
Efforts to elucidate the pathophysiological underpinnings of depression have been
hindered by the heterogeneous classification of the disease. The Research Domain
Criteria (RDoC) initiative (Cuthbert, 2014) spearheaded by the National Institute of
Mental Health has called for the deconstruction of psychiatric syndromes into key
components that can be mapped onto physiological processes. Deficits in motivational
and hedonic processing are a hallmark symptom of depression. Moreover, they are
more prevalent in individuals with a history of excessive stress exposure during
childhood or early development. These observations support exposure to stress as a
critical mediator in the development of depressive phenotypes. Because of the
importance of the nexus between stress and reward, the goal of this thesis research was
to further examine the intersection of brain stress and reward circuitry in the
manifestation and treatment of motivational deficits that contribute to behavioral
phenotypes related to depression.
The research presented in this thesis first characterized the neural substrates
underlying conditioned approach behavior for palatable food, revealing a critical role for
nucleus accumbens (NAc) dopamine (DA) transmission in the acquisition and
maintenance of motivational output for a palatable food reward in mice. These findings
were further expanded to show that exposure to acute stress, as modeled in the noveltyinduced hypophagia (NIH) paradigm, diminished approach behavior and blunted the DA
response to palatable food. Pretreatment with the mixed opioid drug buprenorphine
prevented the neurochemical and behavioral effects of the stressor, thus identifying the
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brain opioid system as a potential pharmacological target for mitigating the aversive
effects of stress on incentive salience for natural rewards. This hypothesis was further
explored by investigating the role of individual opioid receptors in mediating restoration
of conditioned approach behavior in the novelty-induced hypophagia test, leading to the
novel finding that selective antagonism of the mu opioid receptor is sufficient to alleviate
suppressed approach behavior. Lastly, an exogenous corticosterone (CORT)
administration paradigm was employed to examine the interaction between stress
hormones and antidepressant treatment on approach behavior in the NIH paradigm.
Remarkably, CORT treatment potentiated the behavioral effects of the selective
serotonin reuptake inhibitor fluoxetine in a mouse strain that is otherwise non-responsive
to this antidepressant treatment. Altogether, these findings expand our understanding of
how stress impacts neurobiological processes involved in the expression of goaldirected behaviors. Simultaneously, these findings identify novel pharmacological targets
and strategies for the treatment of depressive phenotypes characterized by anhedonia.
NAc DA as a neural underpinning of incentive salience
Multiple lines of evidence support the involvement of the mesocorticolimbic DA system,
specifically the nucleus accumbens (NAc), in the processing of the reward value of a
stimulus. Animals will operantly respond for NAc infusions of agents that increase
extracellular DA (Hoebel et al., 1989; Phillips et al., 1994; Carlezon et al., 1995) and
exhibit conditioned place preference for environments where they received
microinjections of DA agonists into the NAc, (Carr and White, 1983, 1986). However, the
exact role of DA in reward processing per se remains controversial. Early studies posited
that DA regulates the hedonic impact of a stimulus (Wise, 1985; Koob and Le Moal,
1997), though that hypothesis has since been proven unlikely (Berridge et al., 1989).
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Recent empirical evidence supports a role for subcortical DA transmission in
reinforcement learning and attribution of incentive salience, or “wanting”, towards effortworthy goals (Berridge, 2012). Interestingly, exposure to unconditioned novel stimuli in
rats transiently elevates NAc DA and triggers investigatory activity (Rebec et al., 1997;
Legault and Wise, 2001). Similarly, consumption of a novel food, but not a familiar food,
produces robust increases in NAc DA release in the rat (Bassareo and Di Chiara, 1997;
Gambarana et al., 2003). Thus, some have argued that NAc DA promotes exploratory
behaviors that aid in the formation of new motivational connections between salient
stimuli and environmental cues (Ikemoto and Panksepp, 1999). In contrast, the findings
reported in this thesis research propose an alternative role for NAc DA in the processing
of unconditioned versus conditioned stimuli in mice.
The data presented in Chapter 2 established that repeated exposure to palatable
food in a familiar feeding environment is necessary for the acquisition of stable
conditioned approach behavior and the food-evoked DA response in the NAc. The
majority of animals that were naïve to the food reward failed to approach or consume the
food within the fifteen-minute time frame. Furthermore, in comparison to animals familiar
with the food reward, naïve mice exhibited more signs of active avoidance, such as
increased burying and freezing during food presentation. Lastly, animals that were
familiar with the food, but received the food in an unconditioned feeding environment
displayed attenuated NAc DA release and slightly increased (though not reaching
significance) approach latencies compared to those receiving the food reward in a
familiar feeding environment. Altogether, these findings highlight the importance of
environmental context in the acquisition of conditioned approach behavior and
neurochemical response to rewards in the mouse.
These studies also revealed important species differences in the role of the
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mesolimbic DA system in the processing of predictive cues. In rats, anticipatory cues
reliably promote DA release in the NAc across laboratories, whereas reports of
increased DA release to actual consumption of the food reward have been variable
(Cenci et al., 1992; Salamone et al., 1994; Martel and Fantino, 1996; Hajnal and
Norgren, 2001). Consistent with the rat literature, mice exhibited a robust increase in
NAc DA efflux when presented with an empty food dish (predictive stimulus) after being
trained to expect the presentation of food. This finding is in accordance with classical
Pavlovian conditioning theory, which theorizes that a neutral stimulus associated with a
conditioned stimulus can become a conditioned stimulus in and of itself as it acquires the
ability to elicit a conditioned response. Interestingly, the time course for DA response to
the conditioned and predictive stimulus deviated. When presented with the food, animals
displayed elevated DA efflux that persisted throughout the period of food presentation
and after the food had been removed. In contrast, when presented with the empty food
dish, animals displayed a rapid rise in NAc efflux that quickly returned back to baseline.
Thus, DA transmission in the NAc potentially serves both as an anticipatory cue and
consummatory cue, with the latter possibly encoding reinforcement learning for
subsequent exposures.
Stress as an inhibitor of incentive salience
Approach-based behavioral adjustments to salient stimuli are considered one of the
more rudimentary and elemental components of goal-directed behavior (Lewin, 1935;
Schur and Ritvo, 1970; Elliot et al., 2006). Thus, perturbation of the neural mechanisms
that regulate the manifestation of incentive salience likely results in dysfunctional
behavioral output. Previous studies in rats have demonstrated that exposure to chronic
mild stress blunts NAc DA response to palatable food (Di Chiara and Tanda, 1997; Di
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Chiara et al., 1999; Gambarana et al., 2003). The authors concluded that reduced DA
responsiveness to the food reward denotes an anhedonic state. Yet, stressed rats
showed similar approach latencies and food consumption to non-stressed animals. It is
possible that these animals had become so overtrained to the food stimulus that DA
transmission signaling the presence of an anticipatory cue was no longer necessary to
initiate approach behavior. Indeed, it has been suggested that NAc DA transmission is
not necessary for previously learned behaviors or habits but may be more important for
new learning (Ikemoto and Panksepp, 1999). Nonetheless, a lack of notable change in
behavior in these studies makes it difficult to interpret how diminished NAc DA response
influences motivational salience. To address the question of whether disruption of NAc
DA transmission impairs incentive salience we employed a hyponeophagia-based
paradigm in which conditioned approach behavior for palatable food is suppressed by an
acute environmental stressor. We observed that presentation of a bright light and novel
scent during food exposure blunted NAc DA reactivity to the conditioned food stimulus
and increased approach latency without affecting the amount of food consumed. The
fact that stressed animals do eventually approach and consume comparable amounts of
food to non-stressed animals lends support to the hypothesis that conditioned approach
behaviors are not dependent on NAc DA transmission. However, the delay in initial
approach likely reflects alterations in DA mediated incentive salience. For example, DA
may amplify appetitive behavioral states to more readily engage motor systems involved
in approach behavior. Thus, in the absence of DA response, animals are not as
immediately energized towards salient stimuli. Alternatively, suppression of DA response
may alter the valence of a stimulus so that it no longer elicits “wanting”. Further studies
are needed to dissociate these mechanisms.
It is important to note that both appetitive and aversive stimuli evoke activation of
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NAc DA (Abercrombie et al., 1989; Salamone, 1994; Kalivas and Duffy, 1995). However,
recent studies have demonstrated that distinct anatomical regions within the NAc are
differentially modulated depending on the context of the stimuli. Lammel et al. (2011)
demonstrated that rewarding experiences selectively modify excitatory synapses on
dopaminergic cells projecting to the NAc medial shell, whereas aversive stimuli modify
synapses on DA neurons projecting to the mPFC. Similarly, corticolimbic glutamate
signals within the NAc generate appetitive or fearful behavior depending on rostrocaudal
location with the medial shell (Faure et al., 2008). Thus, stress exposure during the
presentation of food might selectively activate a distinct circuitry involved in processing
of aversive stimuli while suppressing signaling pathways associated with motivational
salience.
A role for the mu opioid receptor in mediating incentive salience and stress
One of the more striking findings of Chapter 2 is that pretreatment with buprenorphine
(BPN), a mixed-opioid drug currently in development for the treatment of depression and
anxiety, prevented the stress-induced suppression of NAc DA and restored approach
latencies to that seen in non-stressed animals. These data complement previous studies
conducted in our laboratory showing that acute BPN treatment reduces approach
latencies in the NIH test (Falcon et al., 2015), and suggest a role for opioid systems in
mitigating the aversive effects of stress on incentive salience for natural rewards. This
hypothesis was explored further in Chapter 3 by probing the role of individual opioid
receptors in mediating BPN’s effect on approach behavior in the NIH test.
Buprenorphine is a partial agonist at the mu opioid receptor (MOR) and an
antagonist at the kappa opioid receptor (KOR). Accumulating evidence has linked the
KOR and its endogenous ligand dynorphin to the negative consequences of stress in
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rodents. Acute administration of KOR agonists induces anxiogenic and prodepressive
behaviors in rodents (Maisonneuve et al., 1994; Carlezon et al., 2006; McLaughlin et al.,
2006), whereas treatment with KOR antagonists has been shown to elicit antidepressant
life effects (Mague et al., 2003; Carr et al., 2010; Almatroudi et al., 2015; Falcon et al.,
2015; Huang et al., 2016). Recent studies from our laboratory have confirmed the KOR
as a key mediator of BPN’s effects in tests with predictive validity for antidepressant
efficacy, such as the forced swim test (FST) (Falcon et al., 2016). Therefore, we
originally hypothesized that BPN’s effects in the NIH test are primarily derived from
antagonism at the KOR. However, the work presented in Chapter 3 proved this
hypothesis to be incorrect. We observed that BPN’s effects in the NIH test was
conserved in KOR knockout animals, but abolished in MOR knockout mice. Moreover,
administration of selective KOR antagonist nor-BNI in wildtype mice was ineffective in
reducing approach latencies. The discrepancies between previous findings and those
reported here are unclear. It is possible that inherent strain differences dictate response
to KOR antagonists in this paradigm- the present work is the only of our knowledge to
test the effects of the selective MOR antagonist cyprodime and the selective KOR
antagonist nor-BNI in the NIH test using the C57BL/6 mouse strain. The discrepancies
may also be due in part to differences in procedural definitions of “approach” in the NIH
paradigm. For example, some groups might consider investigatory sniffing or licking as
approach, whereas we took a more conservative determining of approach. To this end,
KOR antagonism may reduce latency to investigate but not to consume. Alternatively, in
our experiments KOR antagonism may have increased exploratory behavior rather than
restoring incentive salience for the food reward. Indeed, KOR antagonists have
previously been shown to increase exploratory behaviors in the elevated plus maze and
open field (Knoll et al., 2007; Bruchas et al., 2009; Wiley et al., 2009; Wittmann et al.,
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2009).
Chapter 3 of this thesis established a novel role for modulation of the MOR in
restoring approach behavior in the NIH test. Given the role of MOR in mediating the
reinforcing properties of rewards, we predicted that BPN’s agonist action at MOR might
underlie its behavioral effects. However, several points of evidence contradict this
original hypothesis. Pharmacological blockade of MOR and KOR with the nonselective
opioid receptor antagonist naltrexone did not abolish BPN’s effects in the NIH test.
Furthermore, administration of morphine alone was not effective in altering suppressed
approach behavior. On the contrary, acute antagonism of MOR was sufficient to reduce
approach latency in the NIH test. This observation suggests that MORs may facilitate
prodepressive behaviors under stressful situations. Stimulation of MORs induces
activation of the hypothalamic-pituitary-adrenal (HPA) axis (Kiritsy-Roy et al., 1986;
Pechnick, 1993). Moreover, CRF significantly enhances the release of β-endorphin and
dynorphin from the hypothalamus in vitro (Nikolarakis et al., 1986). In contrast, MOR
knockout mice exhibit less stress-induced increases in plasma corticosterone
concentrations and reduced anxiety and depressive-like behavior in the elevated plus
maze and FST, respectively (Filliol et al., 2000; Ide et al., 2010). Consequently,
antagonism of MORs during stress exposure may prevent the manifestation of affective
behavior. Notably, studies in healthy human populations have indicated that low doses
of BPN enhance attention for positive emotional cues and reduce sensitivity to fearful
cues (Ipser et al., 2013). Moreover, a recent clinical trial testing the efficacy of
buprenorphine combined with a MOR antagonist revealed significant antidepressant
activity in treatment resistant MDD patients (Ehrich et al., 2015).
Antagonism of MORs during stress exposure may restore incentive behavior in
the NIH paradigm via disinhibition of mesoaccumbens DA transmission in response to
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stress. Stress-induced activation of MORs in the ventral tegmental area (VTA) has been
shown to reduce DA transmission in the NAc through enhanced DA signaling in the
medial prefrontal cortex (mPFC) (Latagliata et al., 2014). This is consistent with previous
findings establishing that in response to an acute stressor, mice of the C57BL/6 inbred
strain exhibit a robust and rapid activation of mesocortical DA release that is
accompanied by inhibition of DA release in the accumbens (Ventura et al., 2002).
Recent studies indicate that activation of VTA DA neurons is differentially modulated by
input-specific circuits. Lammel et al. (2012) demonstrated that laterodorsal tegmentum
(LDTg) neurons predominantly synapse on DA neurons projecting to the NAc lateral
shell and produce conditioned place preference when activated, whereas neurons
originating from the lateral habenula (LHb) synapse primarily on DA neurons projecting
to the mPFC and produce conditioned place aversion. Thus, aversive experiences
appear to selectively activate DA neurons projecting to the mPFC. Acute exposure to
stress or administration of glucocorticoids also produces robust increases in extracellular
glutamate levels preferentially in the PFC (Moghaddam, 1993; Bagley and Moghaddam,
1997; Popoli et al., 2012). Stress-induced enhancement of basal glutamate transmission
is mediated by increased expression of postsynaptic NMDA and AMPA receptors (Yuen
et al., 2009; Yuen et al., 2011). Activation of D1 receptors in the mPFC increases
excitability of glutamatergic pyramidal cells (Tseng and O'Donnell, 2004), which have
been shown to project to the NAc (Carr et al., 1999). Optogenetic activation of
glutamatergic projections in the mPFC suppresses striatal response to DA and
diminishes the reinforcing effects of midbrain DA neuron stimulation (Ferenczi et al.,
2016). This effect may be mediated by stimulation of GABAergic medium spiny output
neurons in the NAc (Sesack and Pickel, 1992). Thus, MOR-induced potentiation of
mPFC dopamine activity in response to stress may lead to blunted mesoaccumbens DA
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release in the mesolimbic pathways, and consequently, diminished incentive behavior in
response to rewards. Alternatively, intra-VTA LHb axonal stimulation has been shown to
inhibit VTA DA neurons projecting to the NAc via increased GABAergic signaling from
the rostromedial tegmental area (RMTg) to the VTA (Lammel et al., 2012). Activation of
MORs expressed on GABAergic neurons in the RMTg putatively increase VTA DA
activity (Matsui and Williams, 2011). However, recent studies have revealed that
GABAergic afferents to dopamine neurons exhibit projection specific sensitivity to
opioids. Specifically, MOR activation induced inhibition of inhibitory postsynaptic currents
(IPSCs) evoked from the RMTg but not VTA interneurons (Matsui et al., 2014). These
findings suggest that opioid-dopamine interactions in the VTA are likely regulated by
complex local circuitry. Indeed, there is evidence that local administration of MOR
antagonists into the VTA can increase striatal dopamine concentrations (Devine et al.,
1993). LHb neurons are known to be excited by the absence of an expected reward
(Hikosaka, 2010), however, both central administration of CRF and exposure to acute
stress increases c-fos activation in the habenula, indicating that this region is also
activated during stress response (Imaki et al., 1993). Thus, presentation of aversive
stimuli with rewarding stimuli may override activation of reward-processing pathways
and subsequent DA release in the NAc by enhancing GABAergic signaling in the VTA.
Accordingly, acute stress exposure has been shown to increase firing of GABAergic
neurons within the VTA (Tan et al., 2012). Future studies are needed to fully elucidate
the role of MORs within this circuitry.
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FIGURE 5.1

Hypothetical mechanism of action for MOR mediated suppression of NAc DA by
stress. Exposure to stress results in the release of stress hormones (denoted by dashed
line) and B-endorphins. Activation of VTA MORs preferentially enhance dopaminergic
signaling in the PFC. Glutamatergic signals from the habenula selectively activate VTA
neurons projecting to the PFC and inhibit VTA DA neurons projecting to the NAc via
activation of GABAergic neurons in the RMTg. The PFC exerts top-down control of NAc
DA activity through dense glutamatergic input to inhibitory GABA neurons that project to
the NAc. Collectively, this circuitry results in reduced DA activity in the NAc and blunted
incentive behavior towards rewarding stimuli.
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Stress as a facilitator of antidepressant response
Whereas Chapters 2 and 3 of this thesis reflected on how stress impairs reward circuitry
and associated motivational behaviors, Chapter 4 proposes a distinctive role for the HPA
stress axis in sensitization of behavioral and neurogenic responses to selective
serotonin reuptake inhibitors (SSRIs), the most commonly prescribed medication for the
treatment of depression. Previous studies have reported the NIH test to be sensitive to
the antidepressant effects of chronic, but not acute, treatment with SSRIs (Bodnoff et al.,
1988; Bodnoff et al., 1989; Dulawa et al., 2004; Dulawa and Hen, 2005; Bechtholt et al.,
2007; David et al., 2009). However, studies conducted in our laboratory (Balu and Lucki,
2009) and others (David et al., 2009) have revealed strain dependent responses to
chronic fluoxetine treatment in the NIH test, showing C57BL/6 mice, in particular, to be
unresponsive to fluoxetine’s effects. The absence of behavioral response to fluoxetine in
this mouse strain may parallel the phenomenon of treatment resistance seen in human
depression (Nemeroff, 2007). We utilized the intrinsic SSRI-insensitivity characteristic of
C57BL/6 mice to investigate strategies for enhancing behavioral sensitivity to this class
of antidepressants in the NIH paradigm.
Hypercortisolism and dexamethasone insensitivity are among the most
consistent pathophysiological findings in depression (Pariante and Miller, 2001; Pariante,
2006; Anacker et al., 2011). Elevated basal cortisol levels are thought to arise from
dysregulation of inhibitory feedback signals to the HPA axis and contribute to affective
behavior. The deficit of negative cortisol feedback is restored in depressed patients after
successful therapeutic treatment with antidepressant drugs (Holsboer et al., 1982).
Accordingly, animals genetically modified to exhibit reduced forebrain corticosteroid
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receptor expression demonstrate elevated CORT levels, hypersensitivity to stressors,
and depressive-like behavior (Ridder et al., 2005; Berger et al., 2006).
The studies in Chapter 4 employed an endogenous CORT exposure paradigm to
examine the influence of dysregulated HPA axis activity on antidepressant response to
chronic fluoxetine treatment in the NIH test. Notably, our chosen method of CORT
exposure (subcutaneous pellet) was ineffective in maintaining persistently elevated
CORT levels, and instead released a large bolus of CORT that rapidly diminished over
the thee week treatment period. Nonetheless, we observed a marked behavioral
response to fluoxetine treatment in the NIH test in animals previously exposed to CORT.
Glucocorticoids have been reported to increase the salience of pleasurable or
compulsive activities. Thus, CORT exposure may prime neurochemical pathways
associated with motivational processing (Dallman et al., 2003). However, animals
exposed to CORT and treated with vehicle did not exhibit reduced approach latencies in
the NIH, suggesting a synergistic interaction between CORT-mediated sensitization and
serotonergic signaling in this paradigm. A potential mechanism for this synergistic effect
may lie in modulation of 5-HT receptor activity. Exposure to chronic mild stress has been
shown to desensitize 5-HT1A autoreceptors in the dorsal raphe (Lanfumey et al., 1999).
Activation of 5-HT1A autoreceptors inhibits serotonin release and subsequent
postsynaptic 5-HT1A receptor activity (Hensler et al., 2007; Lanfumey et al., 2008). Thus,
reduced presence of 5HT1A autoreceptors after CORT exposure may enhance the
therapeutic effects of chronic treatment with fluoxetine by boosting increased
extracellular serotonin levels in forebrain regions. In accordance with this, a small
clinical study conducted in the late 1990s found that dexamethasone therapy
significantly enhanced antidepressant response to SSRIs in treatment resistant patients
(Dinan et al., 1997).
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In Chapter 4 we also showed that reduced novel arena approach latency in
CORT and fluoxetine combination treated animals was associated with a robust increase
in hippocampal neurogenesis. Stress exposure is more commonly reported to reduce
hippocampal cell proliferation in rodents (Cameron and Gould, 1994; Wong and Herbert,
2004; Bilsland et al., 2006; Murray et al., 2008; Brummelte and Galea, 2010). However,
other groups have reported augmented cell proliferation in animals exposed to CORT
and treated with fluoxetine (David et al., 2009). Several groups have reported that
neurogenesis-dependent mechanisms are responsible for the behavioral response to
fluoxetine in the NIH test (Santarelli et al., 2003; Sahay and Hen, 2007; Surget et al.,
2008; Wang et al., 2008; David et al., 2009). In humans, reduced hippocampal volume is
associated with untreated recurrent depression (Sheline et al., 1996; Bremner et al.,
2000; Colla et al., 2007) but not treated depression (Sheline et al., 2003), suggesting
that successful antidepressant treatment can exert critical neuroprotective effects
against chronic stress. Whether reduced hippocampal volume in humans reflects
reduced cell proliferation or other morphological processes is controversial.
Nonetheless, general hippocampal dysfunction is likely to play a role in motivational
processes, seeing as hippocampal synaptic input to the NAc has been shown to mediate
the cognitive functions necessary for initiating goal-directed behavior (Goto and Grace,
2005).
Concluding remarks
This dissertation work has employed a unique and innovative approach to elucidating
mechanisms underlying conditioned approach behavior for natural rewards, an RDoC
construct relevant to the human condition. The focus on a single behavioral paradigm
enabled the methodical assessment of neurochemical and neuropharmacological
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mechanisms specific to stress-induced changes in incentive behavior, thus delivering
new insight into the interactions between brain stress and reward circuitry. The findings
presented here further expand our understanding of the neural correlates of motivation
and propose novel targets for the treatment depression and other psychiatric disorders
characterized by of anhedonia.
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